{
  "name" : "dacemirror.sci-hub.se_journal-article_34d8d8771d527e4536322ee692eda6ed_muka2016.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Estrogen receptor β actions in the female cardiovascular system: A systematic review of animal and human studies",
    "authors" : [ "aulant Muka", "Kris G. Vargas", "Loes Jaspers", "Ke-xin Wen", "Klodian Dhana", "Jana Nano", "Adela Brahimaj", "Veronica Colpani", "Arjola Bano", "ledar Kraja", "Asija Zaciragic", "Wichor M. Bramer", "Gaby M.van Dijk", "aryam Kavousi", "Oscar H. Franco" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "R E s\nT A B M a\nb\nc\nd\na\nA R A\nK E C C V M\nC\nT\nh 0\nMaturitas 86 (2016) 28–43\nContents lists available at ScienceDirect\nMaturitas\njourna l homepage: www.e lsev ier .com/ locate /matur i tas\neview article\nstrogen receptor actions in the female cardiovascular system: A ystematic review of animal and human studies\naulant Muka a,∗, Kris G. Vargas a,1, Loes Jaspers a,1, Ke-xin Wen a, Klodian Dhana a, nna Vitezova a, Jana Nano a, Adela Brahimaj a, Veronica Colpani a, Arjola Bano a, ledar Kraja a,b,c, Asija Zaciragic a, Wichor M. Bramer d, Gaby M.van Dijk a, aryam Kavousi a, Oscar H. Franco a\nDepartment of Epidemiology, Erasmus MC, Rotterdam, The Netherlands Department of Biomedical Sciences, Faculty of Medicine, University of Medicine, Tirana, Albania University Clinic of Gastrohepatology, University Hospital Center Mother Teresa, Tirana, Albania Medical Library, Erasmus MC, Rotterdam, The Netherlands\nr t i c l e i n f o\nrticle history: eceived 9 January 2016 ccepted 14 January 2016\neywords: strogen receptor beta ardiovascular system ardiovascular disease\na b s t r a c t\nFive medical databases were searched for studies that assessed the role of ER in the female cardiovascular system and the influence of age and menopause on ER functioning. Of 9472 references, 88 studies met our inclusion criteria (71 animal model experimental studies, 15 human model experimental studies and 2 population based studies). ER signaling was shown to possess vasodilator and antiangiogenic properties by regulating the activity of nitric oxide, altering membrane ionic permeability in vascular smooth muscle cells, inhibiting vascular smooth muscle cell migration and proliferation and by regulating adrenergic control of the arteries. Also, a possible protective effect of ER signaling against left\nascular endothelium enopause\nventricular hypertrophy and ischemia/reperfusion injury via genomic and non-genomic pathways was suggested in 27 studies. Moreover, 5 studies reported that the vascular effects of ER may be vessel specific and may differ by age and menopause status. ER seems to possess multiple functions in the female cardiovascular system. Further studies are needed to evaluate whether isoform-selective ER -ligands might contribute to cardiovascular disease prevention.\n© 2016 Elsevier Ireland Ltd. All rights reserved.\nontents\n1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 2. Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29\n2.1. Literature search and selection criteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 2.2. Study selection and data extraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 2.3. Outcome assessment and statistical methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 3. Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .30 3.1. General characteristics of included studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 3.2. Vascular reactivity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .30\n3.2.1. Vasoconstriction and vasodilatation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 3.2.2. Endothelial nitric oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS), inducible nitric oxide synthase (iNOS), nitric oxide\nsynthase (NOS) and nitric oxide (NO) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.2.3. Adrenergic control of arteries . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.2.4. Blood pressure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n∗ Corresponding author at: Department of Epidemiology, Erasmus University Medical C he Netherlands.\nE-mail address: t.muka@erasmusmc.nl (T. Muka). 1 Contributed equally.\nttp://dx.doi.org/10.1016/j.maturitas.2016.01.009 378-5122/© 2016 Elsevier Ireland Ltd. All rights reserved.\n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35\nenter, Dr. Molewaterplein 50, Office NA29-14, P.O. Box 2040, 3000 CA Rotterdam,\nT. Muka et al. / Maturitas 86 (2016) 28–43 29\n3.3. Angiogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 3.3.1. Arteriogenesis, capillary formation/density, re-endothelialization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 3.3.2. Protein and gene expression associated with angiogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 3.4. Vascular smooth muscle cell proliferation, apoptosis, migration and inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 3.4.1. Vascular smooth muscle cell proliferation, apoptosis, migration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 3.4.2. Vascular smooth muscle cell and inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 3.5. Proteins and genes in the cardiovascular system . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 3.6. Role of age and menopause status . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 4. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 4.1. Vessel-specific actions of ER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 4.2. ER in left ventricular hypertrophy and ischemic vascular diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 4.3. Role of age, menopause and diabetes in the actions of ER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 4.4. Animal models: ER ligands versus knockout mouse models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 4.5. Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 5. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 Author’s contribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 Sources of funding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 Role of the funder/sponsor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 Provenance and peer review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40\nAcknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .40 Appendix A. Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40\n. . . . . .\n1\nc w p r m d\np o v i e c y i h t i h e m T i o m e t a o [\ne a\n2\n2\n(\nReferences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n. Introduction\nDespite improvements in prevention and treatment, cardiovasular disease (CVD) remains the leading cause of death for women orldwide [1]. Epidemiological studies have revealed that, comared with age-matched men, premenopausal women have a lower isk of coronary heart disease (CHD) which gradually increases after\nenopause so that by the sixth decade women have the same incience of CHD as men [2].\nThe disparity between the incidence of CVD among women in re- and post-menopause has been largely ascribed to the actions f estrogens on the cardiovascular system and, particularly, on the ascular endothelium. Extensive evidence from observational studes suggest cardio-protective effects of endogenous and exogenous strogens in premenopausal women [3]. Similarly, results from linical trials suggest that estrogen therapy started within the first ears after menopause reduce cardiovascular risk’ [4,5]; whereas nitiation of estrogen therapy many years after menopause may ave no or even deleterious cardiovascular effects [5,6]. Therefore, he vascular response to estrogens appears to change with increasng age and to depend on years after menopause. In line with this ypothesis, it has recently been suggested that favorable vascular ffects of estrogen depend on the endothelium and are mediated ainly via estrogen receptors alpha (ER ) and beta (ER ) [7]. herefore, age- and menopause-related endothelial injury, changes n vascular estrogen receptors expression, intracellular signaling r genomics may alter the cardiovascular effects of this sex horone [8]. To date, however, whereas the role of ER has been xtensively studied, the actions of ER on the cardiovascular sysem and the age- and menopause-related changes of vascular ER ctions remain unclear and may explain in part the sex differences bserved in the influence of estrogen on the cardiovascular system 9–11].\nTherefore, we aimed to systematically review the literature valuating the role of ER in the cardiovascular system in females nd the role of age and menopause on ER actions.\n. Methods\n.1. Literature search and selection criteria\nWe conducted a systematic search of electronic databases Embase, Medline, Web of Science, PubMed, Cochrane and Google\n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40\nScholar) until February 5th 2015 (date last searched) to retrieve scientific articles assessing the actions of ER on the cardiovascular system in females and the age- and/or menopause-related changes in vascular ER functions, intracellular signaling or its genomic actions (Appendix A, 2 and 3 in the online Supplemental material). Reference lists of identified articles were also searched and experts in the field were contacted to identify further studies. In total, we found 9472 potentially unique relevant citations.\nStudies were included if the following criteria were fulfilled: (1) the study assessed the effect of ER on vascular reactivity (vasoconstriction, vasodilatation, actions on sympathetic nervous system, pulse wave velocity, blood pressure, vasopressin release, carbon dioxide, adenosine), endothelial function and healing (angiogenesis, vascular smooth muscle cell proliferation and migration or collagen synthesis), endothelium-derived relaxing factor expression (nitric oxide or expression of other endothelium-derived compounds), inflammation, regulation of protein biosynthesis or expression and gene expression in the cardiovascular system, atherosclerosis (including proxies such as carotid intima-media thickness, coronary artery calcium, ankle brachial index, pulse wave velocity) or CVD (CHD, cardiomyopathy, heart failure, cerebrovascular disease, peripheral artery disease and inflammatory heart disease), (2) the study was conducted in females (animal or human) or (if both females and males were included in the studies) the studies that reported the results by gender (or no gender differences were shown), (3) the role of ER was assessed by its gene deletion, use of estrogen receptor agonist, antagonist, antibodies/vectors and its expression levels (4) there was a restriction to the original study results (review and duplicate publications were excluded). The step-wise inclusion and exclusion procedure outline is shown in Fig. 1.\n2.2. Study selection and data extraction\nTwo independent reviewers screened the retrieved titles and abstracts and selected eligible studies. Any disagreement between the two reviewers was resolved through consensus or consultation with a third independent reviewer. A predesigned data collection form was prepared to extract the relevant information from the selected studies, including study design (for human studies), sample type (animal species, number of animal/human participants, age and weight of participants, tissue used, method to assess ER\n30 T. Muka et al. / Maturitas\nRecords identified through database sea rching\n(n = 1528 3 )\nRecords after dupl icates remove d (n =9472)\nRecords scre ened (n =9472)\nRecords ex clu ded based on title and abstract\n(n =9083)\nRecords give n full text detailed ass ess ment\n(n = 389)\nFull-t ext art icles exclu ded (n = 301)\n• Not th e ap propri ate ex pos ure or outcome (n=75) • No female ti ssue or result s not prese nte d gender spe cif ic (n=5 7) • Not the appro pri ate tissue (n=1 4) • Res ults ar e not ER- bet a specif ic (n=22 ) • No full text av ailable (n=6) • Other: data extracti on\nunfeas ible, co nferenc e abstracts, comm entar y , dupl ica tes (n=127)\nStudies included (n =88)\nId en\nfi ca\no n\nEl ig\nib ili\nty\nSc re\nen in g In cl ud ed\nF f\nf c\n2\no b s r r i\n3\nE P A s w o (\n3\ni p 7 t m o t i\nig. 1. Flowchart of studies investigating the role of estrogen receptor beta in the emale cardiovascular system.\nunction, outcome measures and results of the study (author’s conlusion).\n.3. Outcome assessment and statistical methods\nFor each animal model study, we defined whether a positive r negative effect (no effect) result was reported. For populationased studies, we reported the effect magnitude, direction and ignificance. Heterogeneity permitting, we sought to pool the esults using a random effects meta-analysis model. If pooled, the esults were expressed as the pooled estimate and the correspondng 95% confidence intervals.\n. Results\nIn total we identified 15,283 potentially relevant citations via mbase (n = 7161), Medline (n = 3240), Web of Science (n = 4590), ubMed (n = 64), Cochrane (n = 28), Google Scholar (n = 200) (Fig. 1). fter exclusion of duplicates, 9472 references were identified and creened. Based on title and abstracts, full texts of 389 articles ere selected for detailed evaluation. Of those, 88 articles met ur eligibility criteria and were therefore included in the analysis Tables 1A and 1B).\n.1. General characteristics of included studies\nDetailed characteristics of the 88 included studies (86 expermental studies based on animal models or human models and 2 opulation-based studies) are listed in Tables 1A and 1B. There were 1 experimental studies that used animal models (44 studies used issue from mice, 21 from rats, 1 study used combined tissue from\nice and rats and 5 studies used other animal tissue-ewe, rabbit, vine, monkey and swine), 15 experimental studies used human issue and 2 studies were population-based studies. Of the 88 studes included in this review, 17 focused on vascular reactivity, 21 on\n86 (2016) 28–43\nendothelial function and healing, 1 on endothelial-derived relaxing factors, 5 on inflammation, 12 on regulation of protein/gene expression in the cardiovascular system, 1 on atherosclerosis and 31 of the included studies assessed two or more outcome measures. Among the 88 studies included in this review, 4 studies assessed the role of menopause or age on ER function whereas no study assessed the role of ER on cardiovascular disease outcomes in women as endpoint.\n3.2. Vascular reactivity\n3.2.1. Vasoconstriction and vasodilatation Seventeen studies focused on the role of ER in vasoconstriction or vasodilatation (16 animal studies and 1 human study) (Supplemental Table 1A).\n3.2.1.1. ER  ̌ ligands. Eight studies (7 animal model studies and 1 human model study) showed that activation of ER via its agonists (diarylpropionitrile (DPN), Biochanin A and Genistein) was associated with increased relaxation of the vessels (thoracic aorta, inferior vena cava, descending coronary artery, aorta, mesenteric artery; and chorionic and myometrial arteries) [12–19], whereas two studies showed no effect of ER on vascular reactivity (thoracic aorta and mesenteric artery) [20,21]. Furthermore, two studies showed that the effects of ER in vasodilatation are tissue-dependent: one study showed that DPN did not have any effect on relaxation of cephalic and thoracic arteries but provided a significant relaxation in abdominal arteries [22] while the second study showed that the effect of DPN was more potent in the aorta than in the mesenteric artery [14].\nStudies looking at the mechanism of action of ER agonists on vasodilatation were inconsistent. Three studies showed an endothelium-dependent effect of ER on vessel relaxation [16,17,19] while just one study reported that the relaxation caused by ER actions was largely endothelium independent [14]. Three studies showed that relaxation of the vessel due to ER activation was NO-dependent [12,18,19] whereas three other studies showed that vasodilatation due to ER activation was not dependent on NO [13,14,16]. A single study reported that the vessel relaxation induced by DPN was not mediated via the thromboxane receptor pathway [16].\n3.2.1.2. Knockout mouse model. Six studies looked at the effect of ER gene deletion on vasodilatation and showed no consistent results. Three studies reported no effect of ER on endotheliumdependent relaxation in thoracic aorta, the mesenteric artery and femoral arteries [23–25]. One study reported a role of ER on vessel relaxation via extracellular signal-regulated kinase/mitogen activated protein kinase (ERK/MAPK) and phosphatidylinositol3 kinase (PI3K) activation [26]. Two studies reported a direct involvement of ER in mediating vasodilatation exerted by estrogen [25,27]; one study reported that ER may exert a hitherto unrecognised inhibitory influence on the acute dilatory response to estrogen achieved through down regulation of ER -mediated NO release [27].\n3.2.2. Endothelial nitric oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS), inducible nitric oxide synthase (iNOS), nitric oxide synthase (NOS) and nitric oxide (NO)\nTen studies overall (6 animal model studies [15,16,23,28–30] and 4 human model studies [31–34]) focused on the role of ER on eNOS (6 studies), nNOS (1 study), iNOS (2 studies), NOS (1 study) and NO expression (6 studies) (Supplemental Table 1B).\n3.2.2.1. eNOS. Two studies using ER agonists [31,34] reported an increase in eNOS expression due to the activation of ER whereas\nT. M uka et al. / M aturitas 86 (2016) 28–43\n31\n32\nT. M uka et al. / M aturitas 86 (2016) 28–43\nTable 1A (Continued)\nNo. Author Animal type N Age Intact/ovariectomized Tissue Outcome\n23 Guo et al. [26] Mouse 52 80.6 ± 9.7 days Ovariectoized Femoral and carotid artery Vascular reactivity: vasodilatation 24 Gurgen et al. [11] Mouse 5 10 week Intact Aorta/Heart Vascular reactivity: blood pressure 25 Hamada et al. [51] Mouse 17 Ovariectomized Coronary artery ligation and bone\nmarrow transplantation Endothelial function and healing: angiogenesis\n26 Hogg et al. [63] Sprague Dawley rat ND 8 week Intact Smooth muscle cells from aorta • Endothelial function and healing: angiogenesis • Endothelial-derived relaxing factor\n27 Huang et al. [89] Sprague Dawley rat 34 9–11 weeks Intact & ovariectomized\nHeart Protein/gene expression in cardiovascular system\n28 Jayachandran et al. [91] Mouse 20 23–24 months (old) Intact Plasma from retro-orbita sinus plexus Inflammation/oxidative stress 29 Jazbutyte et al. [40] Mouse 71 18 weeks Ovariectomized Descending aorta/Heart • Vascular reactivity: blood pressure\n• Protein/gene expression in cardiovascular system\n30 Jesmin et al. [29] Mouse 36 16 weeks Intact Heart Endothelial function and healing: • Proliferation/apoptosis • Protein/gene expression\n31 Jesmin et al. [15] Mouse 36 15 weeks Intact Cerebral artery Endothelial function and healing: • Proliferation/apoptosis • Protein/gene expression\n32 Jobe et al. [69] Ovine 8 120–147 days Intact Uterine artery endothelial cells Inflammation 33 Kararigas et al. [75] Mouse 8 2 months Intact Heart (transverse aortic constriction) • Protein/gene expression in cardiovascular system\n34 Kararigas et al. [76] Mouse 16 9 week Intact Heart (transverse aortic constriction) Protein/gene expression in cardiovascular system 35 Lee et al. [70] Wistar rat 27 8 weeks ovariactomized Left anterior descending artery Inflammation 36 Li et al. [44] Sprague Dawley Rat ND 3 months Intact Smooth muscle cells from aorta Endothelial function and healing: smooth muscle cell proliferation/apoptosis 37 Liang et al. [50] Mouse ND 3 months ovariactomized Thoracic aorta Endothelial function and healing: protein/gene expression 38 Lin, [57] Mouse 15 8 weeks Ovariectomized Heart Protein/gene expression in cardiovascular system 39 Liu et al. [77] Mouse 12 11–12 weeks Ovariectomized Heart Protein/gene expression in cardiovascular system 40 Luksha et al. [39] Mouse 47 14–22 weeks Intact Femoral arteries Vascular reactivity: adrenergic control 41 Luksha et al. [24] Mouse 47 14–22 weeks Intact Femoral arteries Vascular reactivity: vasodilatation 42 Ma et al. [124] Mouse 7 12 weeks Intact Thoracic aorta Vascular reactivity: vasodilatation 43 Makela et al. [61] Wistar Rat ND 7 day Ovariectomized Smooth muscle cells of carotid artery Endothelial function and healing: smooth muscle cell\nproliferation/apoptosis\nT. M uka et al. / M aturitas 86 (2016) 28–43\n33\nTable 1A (Continued)\nNo. Author Animal type N Age Intact/ovariectomized Tissue Outcome\n44 Mishra et al. [125] Rhesus Macaque monkey\n12 11–20 years old Ovariectomized Coronary smooth muscle cells Endothelial function and healing: protein/gene expression\n45 Nikolic et al. [78] Mouse 44 3 months Ovariectomized Heart (with ischemia reperfusion injury)\nProtein/gene expression in cardiovascular system\n46 Nilsson et al. [25] Mouse 6 6–7 months Intact Abdominal aorta Vascular reactivity: vasodilatation 47 Nudelling et al. [28] Rat ND 1–2 day Intact Cardiomyocite Protein/gene expression in cardiovascular system 48 O’Lone et al. [88] Mouse ND 2,5–11,5 months Ovariectomized Total aortic RNA Protein/gene expression in cardiovascular system 49 Otsuki et al. [79] Mouse 29 11 weeks Intact &\novariectomized Total aortic RNA Protein/gene expression in cardiovascular system\n50 Pedram et al. [80] Mouse ND ND Ovariectomized Cardiac fibroblasts Protein/gene expression in cardiovascular system 51 Pedram et al. [81] Mouse ND 10–12 weeks Intact &\novariectomized Heart Protein/gene expression in cardiovascular system\n52 Pellegrini et al. [62] Sprague Dawley Rat Intact Vascular smooth muscle cells of descending aorta\nEndothelial function and healing: smooth muscle cell proliferation/apoptosis\n53 Pelzer et al. [43] Mouse 89 ND Ovariectomized Left coronary artery/heart • Vascular reactivity: blood pressure • Protein/gene expression in cardiovascular system\n54 Queiros et al. [82] Mouse ND 9–10 weeks Intact Murine cardiomyocite cell line HL-1 and fibroblast\nProtein/gene expression in cardiovascular system\n55 Raffetto et al. [13] Sprague Dawley Rat 6 12 week Intact Inferior vena cava Vascular reactivity: vasodilatation 56 Rayner et al. [85] Mouse 42–54 6 weeks Ovariectomized Aorta/THP-1 human macrophages\nculture Protein/gene expression in cardiovascular system\n57 Reslan et al. [22] Sprague Dawley Rat ND 12 weeks Intact Cephalic, thoracic and abdominal arteries\nVascular reactivity: vasodilatation\n58 Schrepfer et al. [17] Fisher Rat ND ND Ovariectomized Abdominal aorta • Vascular reactivity: vasodilatation • Endothelial function and healing:\nproliferation/apoptosis protein/gene expression\n59 Sebag et al. [73] Mouse 26 7–8 months Intact & ovariectomized\nHeart/Cardiac cell line Protein/Gene expression in cardiovascular system\n60 Shin et al. [53] Mouse 6 10–11 weeks Ovariectomized Transient middle cerebral artery • Protein/gene expression in cardiovascular system • Endothelial function and healing: protein/gene\nexpression\n61 Skavdahl et al. [83] Mouse (transverse aortic constriction)\n49 7 weeks Intact Heart (transverse aortic constriction) • Protein/gene expression in cardiovascular system\n62 Stygar et al. [86] Sprague Dawley Rat 32 8 weeks Ovariectomized Blood from vena cava • Protein/gene expression in cardiovascular system\n63 Traupe et al. [16] Swine 8–20 ND Intact Left anterior descending coronary artery/endothelium\n• Vascular reactivity: Vasodilatation • Endothelial-derived relaxing factor\n64 Wang et al. [84] Mouse 20 12–20 weeks Intact Heart • Protein/gene expression in cardiovascular system • Inflammation\n65 Wang et al. [126] Mouse 20 12–20 weeks Intact Heart Protein/gene expression in cardiovascular system 66 Wang et al. [87] Mouse 60 3 weeks Ovariectomized Heart (transverse aortic constriction) Protein/gene expression in cardiovascular system 67 Xiang et al. [18] Sprague Dawley Rat 8 ND Intact Aorta (collected from a region 1.5 cm\nleft of the aortic arch) Vascular reactivity: vasodilatation\n68 Xing et al. [67] Sprague Dawley Rat ND 10 weeks Intact Aortic smooth muscle cell Inflammation 69 Xing et al. [68] Sprague Dawley Rat ND 10 weeks Intact Aortic smooth muscle cell Inflammation 70 Zhang et al. [54] Ewe ND 145 days Intact Uterine artery endothelial cells Endothelial function and healing: protein/gene expression 71 Zhao et al. [127] Mouse ND 10 weeks Ovariectomized Aortic smooth muscle cell Endothelial function and healing: protein/gene expression\n34\nT. M uka et al. / M aturitas 86 (2016) 28–43\nturitas\na e a d\n3 d o [ i\n3 E s r g\n3 3 m a o v b v [\n3 E t\n3 3 T b a n i\n3 i o r t e\nv m b i ( d b e m p e o e w c b\nT. Muka et al. / Ma\nnother study [28] using ER antagonist showed a decrease in NOS expression. Three knockout mouse model studies reported\ndecrease in eNOS expression [15,30] and phosphorylation [29] ue to the deletion of the ER gene.\n.2.2.2. iNOS, nNOS and NOS. Activation of ER via an ER agonist id not have any effect on iNOS or nNOS expression [31] but the use f an ER antagonist was associated with lower iNOS expression 28]. One study examined the correlation between ER expression n the internal mammary artery and NOS but found none [32].\n.2.2.3. NO. Increase in NO expression with activation of ER via R agonist was reported in two studies [16,34] whereas two other tudies showed no change in NO expression [31,33]. One study [15] eported a decrease in NO production due to the deletion of ER ene whereas another study reported no effect [23].\n.2.3. Adrenergic control of arteries .2.3.1. ERˇ ligands. One study (using human tissue) (Suppleental Table 1B) investigated the role of ER agonist in -2C drenoreceptors expression and reported an increased expression f these receptors [35] ( -2C adrenoreceptors are located on the ascular smooth muscle cells of certain blood vessels and binds oth norepinephrine and epinephrine [36]. Its activation causes asoconstriction of certain arteries, including the coronary artery 37,38]).\n.2.3.2. Knockout mouse model. One study examined the effect of R gene deletion on adrenergic control of arteries (mice femoral issue) and showed no effect [39] (Supplemental Table 1B).\n.2.4. Blood pressure .2.4.1. ERˇ ligands. Three studies (animal models) (Supplemental able 1C) examined the effect of ER agonists 8 -VE2 and DPN on lood pressure: of these, two studies showed a decrease in systolic nd diastolic blood pressure in the aorta and one study showed a on-significant decrease in arterial pressure in the coronary arteres [40–42].\n.2.4.2. Knockout mouse model. There were two studies that examned the role of ER gene deletion on blood pressure regulation r hypertension (Table 2 and Supplemental Table 1B); one study eported that deletion of the ER gene was associated with hyperension (aorta tissue) [11] whereas the other did not report any ffect on systolic blood pressure (coronary artery tissue) [43].\nOverall, the studies looking at ER ligands suggest that actiation of ER via ER agonist may cause relaxation, and therefore ight prevent the pathological effect of excessive vasoconstriction;\nut this may depend on the type of vessel (Table 2). The studes from knockout mouse models are inconsistent in this respect Table 2). The included studies suggest for both an endotheliumependent and −independent action of ER on vascular reactivity; ut the results are contradictory on the mechanisms involved. Nevrtheless, the included studies that used ER ligands or knockout ouse models are consistent in showing a role of ER on eNOS roduction, which might suggest that ER is responsible solely for NOS-derived NO production. The possible mechanisms of action f ER on vascular reactivity are depicted in Fig. 1 and may include NOS, ERK/MAPK and PI3K signaling and adrenoreceptors. In line ith the dilatory effects of ER , the included studies (although not onclusive) suggest that reduced blood pressure may be produced y the activation of ER .\n86 (2016) 28–43 35\n3.3. Angiogenesis\n3.3.1. Arteriogenesis, capillary formation/density, re-endothelialization 3.3.1.1. ER  ̌ ligands. Five studies (1 animal model study [44] and 4 human model studies [45–48]) focused on the role of ER agonists (DPN, Ginsenoside Rb1) in angiogenesis. Four studies [44,46–48] showed anti-angiogenic effects of the ER agonist whereas one study [45] reported no effect on capillary formation (Supplemental Table 2A).\n3.3.1.2. Knockout mouse model. Three studies (animal models) investigated the role of the ER gene deletion on angiogenesis. Two of these studies [49,50] reported no effect and one study [51] reported a reduction in capillary density after the deletion of the ER gene (Supplemental Table 2A). Also, one study[52] showed that ER did not mediate the effect of estrogen in angiogenesis (Supplemental Table 2A).\n3.3.2. Protein and gene expression associated with angiogenesis 3.3.2.1. ER  ̌ ligands. Seven studies (4 animal model studies [17,53–55] and 3 human model studies [45,47,48]) focused on the role of ER agonists on the expression of proteins or genes associated with angiogenesis (Table 2 and Supplemental Table 2B). One study [17] reported that activation of ER was associated with attenuation of vascular cell adhesion protein-1 (VCAM-1) and tumor necrosis alpha (TNF- ) on the rat abdominal aorta whereas no effect was shown on intracellular adhesion molecule (ICAM). In contrast, activation of ER affected the expression of ICAM in human tissue [47]. One study demonstrated that ER activation was associated with decrease of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (which has been shown to increase VEGF expression) in the murine middle cerebral artery [53]. Furthermore, one study reported that ER activation was associated with increased claudin-5 protein and mRNA content [55]. Two studies examining the role of ER activation on s-nitrosylation (SNO) showed contradictory results: one study [54] in animal tissue reported increase in SNO protein expression whereas the other study [45] using human tissue reported no effect. In tissue of premenopausal women, activation of ER was associated with activation of pigment epithelium-derived factor (PEDF) [48]. One study looked at genomic effects in human endothelial cells from the endometrium, myometrium and placenta. It reported that ER activation affected gene expression for 22 out of 99 genes associated with angiogenesis (Growth factors: GRWANG, CXL12, ECGF1, EDIL3, FGF2, GRN, MDK, PDGFB, TGFA, VEGF; Inhibitors: CXCL10, FLT1, IFNB1, SEMA3F, SERPINF1; Markers: CEACAM1, HEY1, Target: ENPP2, NRP2, TIE1, Lymph-angiogenesis: FIGF, FOXC2) [47]. However, this study also showed that there were very few ER - dependent genes common to more than one of the three cell lines used and that several of the shared ER -dependent genes identified were regulated in opposite directions in endometrium and myometrium cell lines [47].\n3.3.2.2. Knockout mouse model. Four studies (3 animal model studies [15,56] and 1 human model [57]) looked at the effect of ER gene deletion on protein or gene expression associated with angiogenesis (Supplemental Table 2B). Two animal studies showed that deletion of the ER gene was associated with a decrease in both VEGF and its kinase insert domain receptors (KDR); and with a reduction in fibroblast growth factor-2 (FGF-2) [15]. One animal study showed an interaction between ER and specificity factor-1 (Sp1) site of the claudin-5 receptor, which consequently induced an increase in claudin-5 expression [56]. One human study showed an inverse association between ER gene deletion in cyclo-oxygenase2 (COX-2) RNA and its protein expression [57].\n36 T. Muka et al. / Maturitas 86 (2016) 28–43\nturitas\ne i B c i w r [ n a c a a t E n p a p a b\n3 m\n3 m\nh m a\n3 p s o p a e o o\n3 r w a\ns\n3 3 o S i e c t M t I I 2 y S\nT. Muka et al. / Ma\nCollectively, these studies provide evidence for anti-angiogenic ffects of ER agonists; whereas knock-out mouse models reported nconsistent results on the role of ER in angiogenesis (Table 2). oth studies using ER ligands or knockout mouse models were onsistent in showing ER to affect VEGF, claudin-5 and FGF-2 n protein and gene expression level; all of which are associated\nith angiogenesis. However, similar to the findings on vascular eactivity, the role of ER on angiogenesis may be vessel-specific 47]. Angiogenesis is the physiological process of formation of ew blood vessels from pre-existing ones and therefore may be\ntarget for combating diseases characterized by either poor vasularization (e.g., ischemic diseases) or abnormal vasculature (e.g., therosclerosis). ER antagonists, by enhancing capillary growth nd increasing blood perfusion in ischemic tissue, can be a novel reatment in cardiac and peripheral ischemia. On the other hand, R agonists may be used in the treatment of atherosclerosis. Since eovascularization is a key factor in the development of advanced laques and is considered a risk factor for plaque rupture [58], ER gonists may be used to improve plaque stability and reduce plaque rogression by inhibiting angiogenesis. In fact, targeting ER with gonists has been reported to be valuable in the treatment of cancer y supressing vascularization [59].\n.4. Vascular smooth muscle cell proliferation, apoptosis, igration and inflammation\n.4.1. Vascular smooth muscle cell proliferation, apoptosis, igration\nEight studies overall (6 animal model [15,17,29,44,60–63] and 2 uman model studies [64,65]) examined the role of ER on smooth uscle cell (SMC) proliferation (6 studies), apoptosis (2 studies) nd migration (3 studies) (Supplemental Table 2C).\n.4.1.1. ERˇ ligands. An inhibitory effect of ER agonists on SMC roliferation were reported in 3 studies [17,44,61] whereas two tudies reported no effect [60,64]. Two studies focused on the role f ER agonists on cell apoptosis and showed enhancement of this rocess with activation of ER [60,65]. Three studies reported an nti-migratory effect by ER [17,61,62]. Two studies showed this ffect was mediated via ER playing a role on the phosphorylation f p38 [60,65] whereas two other studies reported no effect of ER n ERK phosphorylation in the mediation of anti-migration [60,64].\n.4.1.2. Knockout mouse model. One study showed that ER may epress proliferation of SMC by means other than NO signaling [63] hile another study reported ER promoting the activation of propoptotic molecules [15]. One study in humans focused on the role of ER on estradiol ignaling in SMC proliferation and found no effect [66].\n.4.2. Vascular smooth muscle cell and inflammation\n.4.2.1. ERˇ ligands. Two animal studies [67,68] focused on the role f ER agonist DPN on inflammation in vascular endothelium and MC and reported an inhibitory effect of ER on TNF- induced nflammation (Supplemental Table 3). Another study using human ndothelial cells from the endometrium, myometrium and plaenta found that ER activation affected gene expression in 14 of he 92 genes associated with inflammation (Lipase: PCLB2; Kinase:\nAPK3; Prostaglandin metabolism: PTGS1, PTGS2, TBXAS1; Facor: NFKB1; GPCR Receptor: LTB4R, PTAFR, PTGIR, TBXA2R: nterleukin receptor: IL1RL1; Adhesion Molecule: ICAM and TGB2) [47]. One study reported no effect of ER antagonist -phenyl-5,7-bis(trifluoromethyl) pyrazolo [1] [1,5-a]pyrimidin-3l]phenol (PHTPP) on prostacyclin [69] (Supplemental Table 3). imilarly, although not endothelium/SMC specific, two studies\n86 (2016) 28–43 37\nexamining the role of DPN in the thoracic aorta and left anterior descending artery reported no effect of this agonist on TNF- , interleukin-1 beta, C-reactive protein and p-cofilin levels [20,70] (Supplemental Table 3). No studies were found to use a knockout mouse model to examine the role of ER in inflammation.\nOverall, the results from studies using either ER -ligands or knockout mouse models are consistent in supporting antimigratory and pro-apoptotic effects of ER in SMC. Although no consistency was found on the role of ER in SMC proliferation and inflammation (Table 2), the included studies suggest a protective effect of ER against TNF -induced inflammation. SMC migration and apoptosis are key factors in certain vascular diseases. Restenosis, a common adverse event of endovascular procedures to treat the vascular damage from atherosclerosis, is characterized by the sequence of inflammation and SMC proliferation and migration; whereas the role of SMC apoptosis in restenosis remains unclear [58,71]. Also, intimal SMC apoptosis in advanced atherosclerotic plaques may promote plaque rupture while medial apoptosis may promote aneurism formation [71]. Furthermore, SMC apoptosis may be directly pro-inflammatory by triggering the release of chemoattractant and cytokines from inflammatory cells [71]. Therefore, targeting ER through ER agonists may be valuable in the treatment of restenosis. Similarly, the use of ER antagonists may prove to be useful in the treatment of advanced atherosclerotic lesions and aneurisms.\n3.5. Proteins and genes in the cardiovascular system\nTwenty seven studies (in animal models) focused on the role of ER signaling in cardiovascular targets (Supplemental Table 4). Among them, 21 studies [10,30,43,49,57,60,72–87] investigated the molecular mechanism of ER cardioprotective actions against left ventricular hypertrophy and ischemia-reperfusion injury. ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85]. Also, ER was reported to play a role in cardiac fibrosis and inflammation via genomic and non-genomic actions [10,49,76,78,80,82,84,86]. Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78]. Two studies reported no role of ER on stromal cell-derived factor-1 production [89] or on corticotrophin-releasing hormone receptor 2 [90] whereas one study, by using plasma from retro-orbital sinus plexus, showed that deficiency of ER may affect the energy metabolism of platelets resulting in greater production of thrombogenic microvesicles in the circulation [91]. In contrast to the study performed in hearts [78], in which ER selective agonist upregulated 122 genes and down-regulated 23 genes, a gene array study comparing gene expression in ovariectomized mice aorta treated with estrogen showed that 90% of the genes showing an estrogen-mediated decrease, were ER dependent [88].\n3.6. Role of age and menopause status\nOvariectomy was reported to decrease relaxant response of ER -agonist DPN in the rat thoracic aorta; and induction of both ovariectomy and diabetes had synergistic effects on decreasing\n38 T. Muka et al. / Maturitas 86 (2016) 28–43\nF cular e lular s P\nt a m s y s y e a s a r c t o\n4\nt c h o o t w p u p a p v d i i h r b v\nig. 2. Possible mechanism of estrogen receptor beta actions in endothelial and vas NOS, endothelial nitric oxide synthase; ER , estrogen receptor beta; ERK, extracel I3K, phosphatidylinositol-3 kinase.\nhis relaxant response [12]. Also, two studies (one animal [92] nd one human study [93]) focused on the role of ER in inflamation as a function of age and menopausal status. One study howed that estrogen through ER may inhibit inflammation in oung but not in old mice [92], whereas another human study howed an increased linear trend in ER expression with aging and ears since menopause, as well as a positive correlation between xpression of ER and inflammatory markers such as interleukin-8 nd TNF- [93]. In contrast, one (cross-sectional) population-based tudy found that ER correlated with coronary calcification and therosclerosis and tended to be greater correlated in women who eported no use of hormone replacement therapy. However, this orrelation did not differ by menopausal status [94]. Collectively, hese results support the notion that the actions of ER may depend n age, menopausal status and diabetes.\n. Discussion\nBased on the findings from 88 studies, the present review shows hat ER has multiple functions that may contribute to protect the ardiovascular system in women. However, the majority of studies ave been conducted in animals and none has evaluated the role f ERB function and treatment-related strategies on cardiovascular utcomes. The cardiovascular effects of ER signaling could occur hrough multiple mechanisms including a direct effect on the vessel all. ER signaling may cause vasodilation (Fig. 2), and therefore revent the pathological effect of excessive vasoconstriction by reglating the bioavailability of nitric oxide, altering membrane ionic ermeability in vascular smooth muscle cells and by regulating drenergic control of the arteries. Also, ER may have angiogenic roperties that may protect against vascular injury by inhibiting ascular smooth muscle cell migration. (Fig. 2). Furthermore, the ata from this systematic review suggest that ER may have antinflammatory properties mainly by suppressing TNF- -induced nflammation. Supporting the role of ER in vasodilatation, wound ealing, and inflammation, several population-based studies have eported an association between ER gene polymorphisms with lood pressure, inflammatory markers (e.g., TNF- , fibrinogen) and enous ulceration in women [95–101]. Furthermore, various stud-\nsmooth muscles cells. ignal-regulated kinase; MAPK, mitogen activated protein kinase; NO, nitric oxide;\nies have shown that activation of ER has resulted in suppression of IL-6 promoter activity in human endothelial cancer cells in vitro and to play a role in regulation of neutrophil infiltration following acute injury [102,103].\n4.1. Vessel-specific actions of ERˇ\nThe vascular effects of ER may be vessel-specific, and therefore ER may play a role in site-specific vascular diseases such as carotid intimal hyperplasia, peripheral artery disease and thoracic and abdominal aortic aneurysm as well as in localized atherosclerotic disease. Targeting ER with selective receptor agonists or antagonists may be of additional benefit in the treatment of localized vascular disease. For instance, specific ER agonists might be a therapeutic option in occlusive artery disease, whereas ER antagonist may be useful in vascular disease characterized by arterial wall distention and aneurysm. The combination of ER ligands with specific targeting or drug delivery techniques such as drug-eluting stents and perivascular gel might be effective in modulating the activity of ER in a specific blood vessel without altering other vessels in the systemic circulation.\n4.2. ER  ̌ in left ventricular hypertrophy and ischemic vascular diseases\nThe selected studies included in this systematic review indicate a possible protective effect of ER signaling against left ventricular hypertrophy and ischemia/reperfusion injury via genomic and non-genomic pathways (Fig. 3). ER may play a role in the phosphorylation of p38-MAPK, activation of atrial natriuretic factor, inflammatory response, cardiac fibrosis, nitric oxide synthesis and in the regulation of several genes involved in cell metabolism and mitochondrial modeling. Additionally, ER was shown to exert the role of gatekeeper in the genomic response of the heart to pressure overload, and may thus play a protective role against cardiac hypertrophy [76]. These results are in line with the populationbased studies showing an association between polymorphisms of ER gene and homocysteine, nitric oxide, ATP-binding cassette transporter A1 gene expression, left ventricular mass and wall thickness and with the risk of myocardial infarction in women\nT. Muka et al. / Maturitas 86 (2016) 28–43 39\nF C ; PI3K\n[ h t i i f p e f t o d\n4\nd s t n t m o [ a n m w g m s\nig. 3. Possible mechanisms of estrogen receptor beta actions in cardiomyocytes. AMP, cyclic adenosine monophosphate; ERK, extracellular signal-regulated kinase\n104–108]. Based on these experimental data from animal and uman models, subsequent clinical studies are warranted to test if he results of these experimental investigations can be reproduced n interventions conducted in humans and to explore whether soform-selective ER ligands could constitute an effective target or cardiovascular disease treatment. ER might confer the cardiorotective effects of estrogen while avoiding its specific adverse ffects on other tissues such as those of the uterus and breast. In act, targeting ER with agonists has be shown to be valuable in the reatment of certain types of cancers, diminishing several aspects f the malignant process such as proliferation, vascularization, and issemination [109–111].\n.3. Role of age, menopause and diabetes in the actions of ERˇ\nDespite the evidence put forth, the effect of age on the regional istribution of ERs in the heart vessels remains unclear. The expresion of ER nay be vulnerable to the effects of age not only in he cardiovascular system but also in other systems such as the ervous system [112]. It has been suggested that the change in he expression of ERs with aging could be due to variation in\nethylation-associated inactivation of ER gene promoter in varius types of tissues, including those of the cardiovascular system 113,114]. Similarly, loss of locally synthesized estrogen mainly fter menopause can affect the expression of ER [112]. As also oted in this systematic review, ER -mediated vascular actions ay be affected by age, menopause status and diabetes. In line\nith this, it has been reported that diabetes undermines estro-\nen control of inducible NO synthase function in aortic smooth uscle cells through overexpression of ER [115]. In this respect, tudying the differences in ER distribution and activity in the car-\n, phosphatidylinositol-3 kinase, PKA, protein kinase A.\ndiovascular system of young versus old animals, in intact versus ovariectomized females or in non-diabetic and diabetes-induced females could provide further evidence on the potential usefulness of a specific estrogen receptor agonist/antagonist to be used during and after menopause. Furthermore, it may be of interest to investigate the mechanisms regulating the localization of ER ; for instance, future research may focus on whether age-related alterations in NO signaling can contribute to the age-related differences in ER expression and signaling.\n4.4. Animal models: ER  ̌ ligands versus knockout mouse models\nNotably, the protective role of ER in the cardiovascular system was consistently shown in studies using ER agonist/antagonist whereas some discrepancies with the results of the studies using knockout mice were observed (Table 2). These differences could be related to the animal model used and/or different tissue examined. In knockout mice studies, since ER has a lower affinity for estradiol, estradiol concentrations may not be sufficiently high to affect ER signaling. In contrast, local administration of ER agonists can result in more potent activation of ER signaling. Furthermore, the intervention at a certain time point in the knockout mice models may result in potential compensatory mechanisms which may ultimately affect ER signaling. Also, since the discovery of ER , certain mice strains have been genetically modified to delete their ER gene, which have shown markedly different phenotypes [116,117] This may also add to the discrepancies found in the reported results [116]. Therefore, further research is required to better elucidate the differences between studies using animal models and ER agonists/antagonists.\n4 turitas\n4\ns o c n d n l f c r t c m u c a s i t\n5\ne l c t w w\nA\na s o d p K a c a A\nS\no c p m p\nR\nc a d r\n0 T. Muka et al. / Ma\n.5. Limitations\nTo our knowledge, this is the first systematic review on the ubject that critically appraised the literature following an a priri designed protocol with clearly defined inclusion and exclusion riteria. After a systemic search in major electronic databases, few arrative or expert reviews evaluating the role of ER in the cariovascular system were found [118–120]. They were all expert or arrative reviews without a systematic search. Nevertheless, some imitations from the included studies in this review merit careul consideration. Some of the results should be interpreted with autions. For instance, six of 15 human studies included in this eview used umbilical vein endothelial cells for which the sex of he donor was not reported [121]. This may explain some of the disrepancies in the reported results. Although every effort has been ade to undertake a comprehensive search of the published and npublished literature, we cannot exclude the possibility of publiation bias from underreporting of negative findings. Furthermore,\nmeaningful quantitative pooling of the existing data was unfeaible due to different animals and tissues used as samples in the ncluded studies, heterogeneity in the input parameters, assumpions and the study designs.\n. Conclusion\nIn summary, this systematic review summarizes all the available vidence on the role of ER signaling in the female cardiovascuar system through multiple mechanisms. Although these findings ontribute with the generation of hypotheses and the identificaion of potential therapeutic targets, the majority of the studies ere conducted in animals and further evaluations in humans are arranted.\nuthor’s contribution\nThe contribution of the authors were as follows: TM designed nd performed the literature review, designed the search strategy, creened title/abstract, obtained full text, determined eligibility f articles, participated in data extraction, data synthesis/analysis, ata interpretation, coordination, writing the manuscript and was rimary author of the manuscript. TM and OHF conceived the study. GV, LJ, WH, KD, AV, JN, AB, VC, AB, and BK screened title/abstract nd full texts of the included articles. All authors contributed to the ritical revision of the manuscript. OHF participated in study design nd drafting of the final manuscript. TM and OHF are guarantors. ll authors approved the final version.\nources of funding\nThis study was sponsored and funded by Metagenics Inc. Role f the Funder/Sponsor: Metagenics Inc. had no role in design and onduct of the study; collection, management, analysis, and interretation of the data; and preparation, review or approval of the anuscript. The funder/sponsor did not have the ability to veto ublication of study results.\nole of the funder/sponsor\nMetagenics Inc., had no role in design and conduct of the study; ollection, management, analysis, and interpretation of the data; nd preparation, review or approval of the manuscript. The funer/sponsor did not have the ability to veto publication of study esults.\n86 (2016) 28–43\nProvenance and peer review\nNot commissioned; externally peer reviewed.\nAcknowledgements\nTM, LJ, KW, GMD and OHF work in ErasmusAGE, a center for aging research across the life course funded by Nestlé Nutrition (Nestec Ltd.), Metagenics Inc. and AXA. Nestlé Nutrition (Nestec Ltd.), KD, AV, JN, AB, AB, BK and AZ have been financially supported by Erasmus Mundus Western Balkans (ERAWEB), a project funded by the European Commission. These funding sources had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review or approval of the manuscript. KGV and VC have nothing to disclose.\nAppendix A. Supplementary data\nSupplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.maturitas.2016. 01.009.\nReferences\n[1] S. Yusuf, S. Reddy, S. Ounpuu, S. Anand, Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization, Circulation 104 (2001) 2746–2753. [2] J.C. Witteman, D.E. Grobbee, F.J. Kok, A. Hofman, H.A. Valkenburg, Increased risk of atherosclerosis in women after the menopause, BMJ 298 (1989) 642–644. [3] X.P. Yang, J.F. Reckelhoff, Estrogen, hormonal replacement therapy and cardiovascular disease, Curr. Opin. Nephrol. Hypertens. 20 (2011) 133–138. [4] S.R. Salpeter, J.M. Walsh, E. Greyber, E.E. Salpeter, Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis, J. Gen. Intern. Med. 21 (2006) 363–366. [5] J.E. Rossouw, R.L. Prentice, J.E. Manson, L. Wu, D. Barad, V.M. Barnabei, et al., Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause, JAMA 297 (2007) 1465–1477. [6] M. Barton, M.R. Meyer, E. Haas, Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits, Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1669–1672. [7] K.K. Koh, Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy, Int. J. Cardiol. 87 (2003) 1–8. [8] E. Murphy, Estrogen signaling and cardiovascular disease, Circ. Res. 109 (2011) 687–696. [9] E. Dworatzek, S. Mahmoodzadeh, C. Schubert, C. Westphal, J. Leber, A. Kusch, et al., Sex differences in exercise-induced physiological myocardial hypertrophy are modulated by oestrogen receptor beta, Cardiovasc. Res. 102 (2014) 418–428.\n[10] Fliegner D, Schubert C, Penkalla A, Witt H, Kararigas G, Dworatzek E, et al. Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. [Erratum appears in Am J Physiol Regul Integr Comp Physiol. 2010 Sep;299(3):R981 Note: Kararigas, George [corrected to Kararigas, Georgios]]. AM J PHYSIOL REGUL INTEGR COMP PHYSIOL. 2010; 298: R1597-606. [11] D. Gurgen, B. Hegner, A. Kusch, R. Catar, L. Chaykovska, U. Hoff, et al., Estrogen receptor-(beta) signals left ventricular hypertrophy sex differences in normotensive deoxycorticosterone acetate-salt mice, Hypertension 57 (2011) 648–654. [12] T. Akhayeva, N. Ari, G. Ozansoy, The acute relaxant effects of estrogen receptor agonists in diabetic-ovariectomized rat aorta, Turk. J. Pharm. Sci. 8 (2011) 133–146. [13] J.D. Raffetto, X. Qiao, K.G. Beauregard, R.A. Khalil, Estrogen receptor-mediated enhancement of venous relaxation in female rat: implications in sex-related differences in varicose veins, J. Vasc. Surg. 51 (2010) 972–981. [14] K. Al Zubair, A. Razak, S. Bexis, J.R. Docherty, Relaxations to oestrogen receptor subtype selective agonists in rat and mouse arteries, Eur. J. Pharmacol. 513 (2005) 101–108. [15] S. Jesmin, C.N. Mowa, S.N. Sultana, N. Shimojo, H. Togashi, Y. Iwashima, et al., VEGF signaling is disrupted in the hearts of mice lacking estrogen receptor alpha, Eur. J. Pharmacol. 641 (2010) 168–178. [16] T. Traupe, C.D. Stettler, H. Li, E. Haas, I. Bhattacharya, R. Minotti, et al.,\nDistinct roles of estrogen receptors (alpha) and (beta) mediating acute vasodilation of epicardial coronary arteries, Hypertension 49 (2007) 1364–1370.\n[17] S. Schrepfer, T. Deuse, T. Munzel, H. Schafer, W. Braendle, H. Reichenspurner, The selective estrogen receptor-(beta) agonist biochanin A\nturitas T. Muka et al. / Ma\nshows vasculoprotective effects without uterotrophic activity, Menopause 13 (2006) 489–499.\n[18] Q. Xiang, G. Lin, X. Fu, S. Wang, T. Wang, The role of peroxisome proliferator-activated receptor-(gamma) and estrogen receptors in genistein-induced regulation of vascular tone in female rat aortas, Pharmacology 86 (2010) 117–124. [19] J.J. Corcoran, C. Nicholson, M. Sweeney, J.C. Charnock, S.C. Robson, M. Westwood, et al., Human uterine and placental arteries exhibit tissue-specific acute responses to 17(beta)-estradiol and estrogen-receptor-specific agonists, Mol. Hum. Reprod. 20 (2014) 433–441. [20] S. Bansal, K. Chopra, Distinct role of estrogen receptor-alpha and beta on postmenopausal diabetes-induced vascular dysfunction, Gen. Comp. Endocrinol. (2014). [21] C. Bolego, A. Cignarella, P. Sanvito, V. Pelosi, F. Pellegatta, L. Puglisi, et al., The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-(alpha) agonists and is abolished by estrogen deprivation, J. Pharmacol. Exp. Ther. 313 (2005) 1203–1208. [22] O.M. Reslan, Z. Yin, G.R.A. Do Nascimento, R.A. Khalil, Subtype-specific estrogen receptor-mediated vasodilator activity in the cephalic, thoracic, and abdominal vasculature of female rat, J. Cardiovasc. Pharmacol. 62 (2013) 26–40. [23] B. Darblade, C. Pendaries, A. Krust, S. Dupont, M.J. Fouque, J. Rami, et al., Estradiol alters nitric oxide production in the mouse aorta through the (alpha)-, but not (beta)-, estrogen receptor, Circ. Res. 90 (2002) 413–419. [24] L. Luksha, L. Poston, J.A. Gustafsson, K. Hultenby, K. Kublickiene, The oestrogen receptor (beta) contributes to sex related differences in endothelial function of murine small arteries via EDHF, J. Physiol. 577 (2006) 945–955. [25] B.O. Nilsson, E. Ekblad, T. Heine, J.A. Gustafsson, Increased magnitude of relaxation to oestrogen in aorta from oestrogen receptor (beta) knock-out mice, J. Endocrinol. 166 (2000) R5–R9. [26] X. Guo, M. Razandi, A. Pedram, G. Kassab, E.R. Levin, Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors (alpha) and (beta), J. Biol. Chem. 280 (2005) 19704–19710. [27] M.N. Cruz, G. Douglas, J.A. Gustafsson, L. Poston, K. Kublickiene, Dilatory responses to estrogenic compounds in small femoral arteries of male and female estrogen receptor-(beta) knockout mice, Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H823–H829. [28] S. Nuedling, R.H. Karas, M.E. Mendelsohn, J.A. Katzenellenbogen, B.S. Katzenellenbogen, R. Meyer, et al., Activation of estrogen receptor (beta) is a prerequisite for estrogen-dependent upregulation of nitric oxide synthases in neonatal rat cardiac myocytes, FEBS Lett. 502 (2001) 103–108. [29] S. Jesmin, C.N. Mowa, S.N. Sultana, S. Mia, R. Islam, S. Zaedi, et al., Estrogen receptor alpha and beta are both involved in the cerebral VEGF/Akt/NO pathway and cerebral angiogenesis in female mice, Biomed. Res. (Japan) 31 (2010) 337–346. [30] S.A. Gabel, V.R. Walker, R.E. London, C. Steenbergen, K.S. Korach, E. Murphy, Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury, J. Mol. Cell. Cardiol. 38 (2005) 289–297. [31] S. Chakrabarti, O. Lekontseva, A. Peters, S.T. Davidge, 17(beta)-Estradiol induces protein S-nitrosylation in the endothelium, Cardiovasc. Res. 85 (2010) 796–805. [32] M. Sitges, A. Leivas, M. Heras, E. Ferrer, M. Roque, D. Viles, et al., Short-term transdermal estradiol enhances nitric oxide synthase III and estrogen receptor mRNA expression in arteries of women with coronary artery disease, Int. J. Cardiol. 105 (2005) 74–79. [33] S. Novella, A. Laguna-Fernandez, M. Lazaro-Franco, A. Sobrino, C. Bueno-Beti, J.J. Tarin, et al., Estradiol, acting through estrogen receptor alpha, restores dimethylarginine dimethylaminohydrolase activity and nitric oxide production in oxLDL-treated human arterial endothelial cells, Mol. Cell. Endocrinol. 365 (2013) 11–16. [34] T. Simoncini, L. Fornari, P. Mannella, A. Caruso, S. Garibaldi, C. Baldacci, et al., Activation of nitric oxide synthesis in human endothelial cells by red clover extracts, Menopause 12 (2005) 69–77. [35] A.H. Eid, K. Maiti, S. Mitra, M.A. Chotani, S. Flavahan, S.R. Bailey, et al., Estrogen increases smooth muscle expression of (alpha) 2C-adrenoceptors and cold-induced constriction of cutaneous arteries, Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H1955–H1961. [36] Boron, F. W. Medical Physiology: A Cellular and Molecular Approach. 2012:360. [37] LS G, LG, H, LE L, AG. G. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. Tenth Edition. McGraw-Hill. 2001:140. [38] O.L. Woodman, S.F. Vatner, Coronary vasoconstriction mediated by alpha-1-adrenoceptors and alpha-2-adrenoceptors in conscious dogs, Am. J. Physiol. 253 (1987) H388–H393. [39] L. Luksha, L. Poston, J.A. Gustafsson, L. Aghajanova, K. Kublickiene, Gender-specific alteration of adrenergic responses in small femoral arteries from estrogen receptor-(beta) knockout mice, Hypertension 46 (2005) 1163–1168. [40] V. Jazbutyte, P.A. Arias-Loza, K. Hu, J. Widder, V. Govindaraj, C. Von\nPoser-Klein, et al., Ligand-dependent activation of ER(beta) lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats, Cardiovasc. Res. 77 (2008) 774–781.\n[41] P.A. Arias-Loza, K. Hu, C. Dienesch, A.M. Mehlich, S. Konig, V. Jazbutyte, et al., Both estrogen receptor subtypes, (alpha) and (beta), attenuate\n86 (2016) 28–43 41\ncardiovascular remodeling in aldosterone salt-treated rats, Hypertension 50 (2007) 432–438. [42] E.A. Booth, N.R. Obeid, B.R. Lucchesi, Activation of estrogen receptor-(alpha) protects the in vivo rabbit heart from ischemia-reperfusion injury, Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H2039–H2047. [43] T. Pelzer, P.A.A. Loza, K. Hu, B. Bayer, C. Dienesch, L. Calvillo, et al., Increased mortality and aggravation of heart failure in estrogen receptor-(beta) knockout mice after myocardial infarction, Circulation 111 (2005) 1492–1498. [44] Q.Y. Li, L. Chen, Y.H. Zhu, M. Zhang, Y.P. Wang, M.W. Wang, Involvement of estrogen receptor-B in farrerol inhibition of rat thoracic aorta vascular smooth muscle cell proliferation, Acta Pharmacol. Sin. 32 (2011) 433–440. [45] I. Baruscotti, F. Barchiesi, E.K. Jackson, B. Imthurn, R. Stiller, J.H. Kim, et al., Estradiol stimulates capillary formation by human endothelial progenitor cells: Role of estrogen receptor-(alpha)/(beta), heme oxygenase 1, and tyrosine kinase, Hypertension 56 (2010) 397–404. [46] A. Giddabasappa, J.R. Eswaraka, C.M. Barrett, M.N. Bauler, Z. Wu, M. Yepuru, et al., (beta)-LGND2, an ER(beta) selective agonist, inhibits pathologic retinal neovascularization, Invest. Ophthalmol. Vis. Sci. 53 (2012) 5066–5075. [47] E. Greaves, F. Collins, H.O.D. Critchley, P.T.K. Saunders, ER(beta)-dependent effects on uterine endothelial cells are cell specific and mediated via Sp1, Hum. Reprod. 28 (2013) 2490–2501. [48] K.W. Leung, L.W.T. Cheung, Y.L. Pon, R.N.S. Wong, N.K. Mak, T.P.P. Fan, et al., Ginsenoside Rb1 inhibits tube-like structure formation of endothelial cells by regulating pigment epithelium-derived factor through the oestrogen (beta) receptor, Br. J. Pharmacol. 152 (2007) 207–215. [49] A.M. Broberg, A.J. Siddiqui, H. Fischer, K.H. Grinnemo, E. Wardell, A.B. Andersson, et al., Estrogen receptors do not influence angiogenesis after myocardial infarction, Scand. Cardiovasc. J. 45 (2011) 215–222. [50] M. Liang, E. Ekblad, J.A. Gustafsson, B.O. Nilsson, Stimulation of vascular protein synthesis by activation of oestrogen receptor (beta), J. Endocrinol. 171 (2001) 417–423. [51] H. Hamada, M.K. Kim, A. Iwakura, M. Ii, T. Thorne, G. Qin, et al., Estrogen receptors (alpha) and (beta) mediate contribution of bone marrow-derived endothelial progenitor cells to functional recovery after myocardial infarction, Circulation 114 (2006) 2261–2270. [52] L. Brouchet, A. Krust, S. Dupont, P. Chambon, F. Bayard, J.F. Arnal, Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-(alpha) but not estrogen receptor-(beta), Circulation 103 (2001) 423–428. [53] J.A. Shin, S.J. Yang, S.I. Jeong, H.J. Park, Y.H. Choi, E.M. Park, Activation of estrogen receptor (beta) reduces blood–brain barrier breakdown following ischemic injury, Neuroscience 235 (2013) 165–173. [54] H.H. Zhang, L. Feng, W. Wang, R.R. Magness, D.B. Chen, Estrogen-responsive nitroso-proteome in uterine artery endothelial cells: role of endothelial nitric oxide synthase and estrogen receptor-(beta), J. Cell. Physiol. 227 (2012) 146–159. [55] M. Burek, P.A. Arias-Loza, N. Roewer, C.Y. Forster, Claudin-5 as a novel estrogen target in vascular endothelium, Arterioscler. Thromb. Vasc. Biol. 30 (2010) 298–304. [56] M. Burek, K. Steinberg, C.Y. Forster, Mechanisms of transcriptional activation of the mouse claudin-5 promoter by estrogen receptor alpha and beta, Mol. Cell. Endocrinol. 392 (2014) 144–151. [57] E.J. Su, Z.H. Lin, R. Zeine, P. Yin, S. Reierstad, J.E. Innes, et al., Estrogen receptor-beta mediates cyclooxygenase-2 expression and vascular prostanoid levels in human placental villous endothelial cells, Am. J. Obstet. Gynecol. 200 (427) (2009) e1–e8. [58] S.F. Louis, P. Zahradka, Vascular smooth muscle cell motility: from migration to invasion, Exp. Clin. Cardiol. 15 (2010) e75–e85. [59] K. Yakimchuk, M.S. Hasni, J. Guan, M.P. Chao, B. Sander, S. Okret, Inhibition of lymphoma vascularization and dissemination by estrogen receptor beta agonists, Blood 123 (2014) 2054–2061. [60] B. Cheng, J. Song, Y. Zou, Q. Wang, Y. Lei, C. Zhu, et al., Responses of vascular smooth muscle cells to estrogen are dependent on balance between ERK and p38 MAPK pathway activities, Int. J. Cardiol. 134 (2009) 356–365. [61] S. Makela, H. Savolainen, E. Aavik, M. Myllarniemi, L. Strauss, E. Taskinen, et al., Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors (alpha) and (beta), Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 7077–7082. [62] M. Pellegrini, P. Bulzomi, M. Lecis, S. Leone, I. Campesi, F. Franconi, et al., Endocrine disruptors differently influence estrogen receptor (beta) and androgen receptor in male and female rat VSMC, J. Cell. Physiol. 229 (2014) 1061–1068. [63] M.E. Hogg, A.K. Vavra, M.N. Banerjee, J. Martinez, Q. Jiang, L.K. Keefer, et al., The role of estrogen receptor (alpha) and (beta) in regulating vascular smooth muscle cell proliferation is based on sex, J. Surg. Res. 173 (2012) e1–e10. [64] J. Ortmann, M. Veit, S. Zingg, S. Di Santo, T. Traupe, Z. Yang, et al., Estrogen receptor-(alpha) but not -(beta) or GPER inhibits high glucose-induced human VSMC proliferation: potential role of ROS and ERK, J. Clin. Endocrinol. Metab. 96 (2011) 220–228. [65] S.Z. Xu, W. Zhong, M. Ghavideldarestani, R. Saurabh, S.W. Lindow, S.L. Atkin, Multiple mechanisms of soy isoflavones against oxidative stress-induced endothelium injury, Free Radic. Biol. Med. 47 (2009) 167–175. [66] Y. Nakamura, T. Suzuki, Y. Miki, C. Tazawa, K. Senzaki, T. Moriya, et al., Estrogen receptors in atherosclerotic human aorta: inhibition of human\n4 turitas 2 T. Muka et al. / Ma\nvascular smooth muscle cell proliferation by estrogens, Mol. Cell.Endocrinol. 219 (2004) 17–26. [67] D. Xing, W. Feng, A.P. Miller, N.M. Weathington, Y.F. Chen, L. Novak, et al., Estrogen modulates TNF-(alpha)-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-(beta) activation, Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H2607–H2612. [68] D. Xing, S. Oparil, H. Yu, K. Gong, W. Feng, J. Black, et al., Estrogen modulates NF(kappa)B signaling by enhancing I(kappa)B(alpha) levels and blocking p65 binding at the promoters of inflammatory genes via estrogen receptor-(beta), PLoS One 7 (6) (2012) e36890. [69] S.O. Jobe, J. Ramadoss, J.M. Koch, Y. Jiang, J. Zheng, R.R. Magness, Estradiol-17(beta) and its cytochrome P450-and catechol-Omethyltransferase-derived metabolites stimulate proliferation in uterine artery endothelial cells: role of estrogen receptor-(alpha) versus estrogen receptor-(beta), Hypertension 55 (2010) 1005–1011. [70] T.M. Lee, S.Z. Lin, N.C. Chang, Membrane ER(alpha) attenuates myocardial fibrosis via RhoA/ROCK-mediated actin remodeling in ovariectomized female infarcted rats, J. Mol. Med. 92 (2014) 43–51. [71] M.R. Bennett, Apoptosis in the cardiovascular system, Heart 87 (2002) 480–487. [72] X. Gao, Q. Liang, Y. Chen, H.S. Wang, Molecular mechanisms underlying the rapid arrhythmogenic action of bisphenol A in female rat hearts, Endocrinology 154 (2013) 4607–4617. [73] I.A. Sebag, M.A. Gillis, A. Calderone, A. Kasneci, M. Meilleur, R. Haddad, et al., Sex hormone control of left ventricular structure/function: mechanistic insights using echocardiography, expression, and DNA methylation analyses in adult mice, Am. J. Physiol. Heart Circ. Physiol. 301 (2011) H1706–H1715. [74] F.A. Babiker, D. Lips, R. Meyer, et al., Estrogen receptor beta protects the murine heart against left ventricular hypertrophy, Arterioscler. Thromb. Vasc. Biol. 26 (7) (2006) 1524–1530. [75] G. Kararigas, D. Fliegner, S. Forler, O. Klein, C. Schubert, J.A. Gustafsson, et al., Comparative proteomic analysis reveals sex and estrogen receptor beta effects in the pressure overloaded heart, J. Proteome Res. 13 (12) (2014) 5829–5836. [76] G. Kararigas, D. Fliegner, J.A. Gustafsson, V. Regitz-Zagrosek, Role of the estrogen/estrogen-receptor-beta axis in the genomic response to pressure overload-induced hypertrophy, Physiol. Genomics. 43 (2011) 438–446. [77] D. Liu, A. Deschamps, K.S. Korach, E. Murphy, Estrogen-enhanced gene expression of lipoprotein lipase in heart is antagonized by progesterone, Endocrinology 149 (2008) 711–716. [78] I. Nikolic, D. Liu, J.A. Bell, J. Collins, C. Steenbergen, E. Murphy, Treatment with an estrogen receptor-beta-selective agonist is cardioprotective, J. Mol. Cell. Cardiol. 42 (2007) 769–780. [79] M. Otsuki, H. Gao, K. Dahlman-Wright, C. Ohlsson, N. Eguchi, Y. Urade, et al., Specific regulation of lipocalin-type prostaglandin D synthase in mouse heart by estrogen receptor (beta), Mol. Endocrinol. 17 (2003) 1844–1855. [80] A. Pedram, M. Razandi, F.O. Mahony, Dennis Lubahn, R. Ellis Levin, Estrogen receptor- prevents cardiac fibrosis, Mol. Endocrinol. 24 (11) (2010) 2152–2165. [81] A. Pedrama, M. Razandi, R. Narayanan, J.T. Dalton, T.A. McKinsey, E.R. Levin, Estrogen regulates histone deacetylases to prevent cardiac hypertrophy, Mol. Biol. Cell. 24 (2013) 3805–3818. [82] A.M. Queiros, C. Eschen, D. Fliegner, G. Kararigas, E. Dworatzek, C. Westphal, et al., Sex- and estrogen-dependent regulation of a miRNA network in the healthy and hypertrophied heart, Int. J. Cardiol. 169 (2013) 331–338. [83] M. Skavdahl, C. Steenbergen, J. Clark, P. Myers, T. Demianenko, L. Mao, et al., Estrogen receptor-(beta) mediates male-female differences in the development of pressure overload hypertrophy, Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H469–H476. [84] M. Wang, P.R. Crisostomo, T. Markel, Y. Wang, K.D. Lillemoe, D.R. Meldrum, Estrogen receptor beta mediates acute myocardial protection following ischemia, Surgery (USA) 144 (2008) 233–238. [85] K. Rayner, J. Sun, Y.X. Chen, M. McNulty, T. Simard, X. Zhao, et al., Heat shock protein 27 protects against atherogenesis via an estrogen-dependent mechanism: role of selective estrogen receptor beta modulation, Arterioscler. Thromb. Vasc. Biol. 29 (2009) 1751–1756. [86] D. Stygar, B. Masironi, H. Eriksson, L. Sahlin, Studies on estrogen receptor (ER) (alpha) and (beta) responses on gene regulation in peripheral blood leukocytes in vivo using selective ER agonists, J. Endocrinol. 194 (2007) 101–119. [87] Y.C. Wang, X.L. Xiao, N. Li, D. Yang, Y. Xing, R. Huo, et al., Oestrogen inhibits BMP4-induced BMP4 expression in cardiomyocytes: a potential mechanism of oestrogen-mediated protection against cardiac hypertrophy, Br. J. Pharmacol. (2015). [88] R. O’Lone, K. Knorr, I.Z. Jaffe, M.E. Schaffer, P.G.V. Martini, R.H. Karas, et al., Estrogen receptors (alpha) and (beta) mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species, Mol. Endocrinol. 21 (2007) 1281–1296. [89] C. Huang, H. Gu, Y. Wang, M. Wang, Estrogen-induced SDF-1 production is mediated by estrogen receptor-(alpha) in female hearts after acute ischemia\nand reperfusion, Surgery (USA) 150 (2011) 197–203.\n[90] B.H. Cong, Y.J. Xu, H. Sheng, X.Y. Zhu, L. Wang, W. Zhao, et al., Cardioprotection of 17 beta-estradiol against hypoxia/reoxygenation in cardiomyocytes is partly through up-regulation of CRH receptor type 2, Mol. Cell. Endocrinol. 382 (2014) 17–25.\n86 (2016) 28–43\n[91] M. Jayachandran, C.C. Preston, L.W. Hunter, A. Jahangir, W.G. Owen, K.S. Korach, et al., Loss of estrogen receptor (beta) decreases mitochondrial energetic potential and increases thrombogenicity of platelets in aged female mice, Age 32 (2010) 109–121. [92] M.R. Bowling, D. Xing, A. Kapadia, Y.F. Chen, A.J. Szalai, S. Oparil, et al., Estrogen effects on vascular inflammation are age dependent: role of estrogen receptors, Arterioscler. Thromb. Vasc. Biol. 34 (2014) 1477–1485. [93] S. Novella, M. Heras, C. Hermenegildo, A.P. Dantas, Effects of estrogen on vascular inflammation: a matter of timing, Arterioscler. Thromb. Vasc. Biol. 32 (2012) 2035–2042. [94] R.C. Christian, P.Y. Liu, S. Harrington, M. Ruan, V.M. Miller, L.A. Fitzpatrick, Intimal estrogen receptor (ER) beta, but not ERalpha expression, is correlated with coronary calcification and atherosclerosis in pre- and postmenopausal women, J. Clin. Endocrinol. Metab. 91 (2006) 2713–2720. [95] A.M. Alessio, N.F. Hoehr, L.H. Siqueira, M.C. Ozelo, A. de Padua Mansur, J.M. Annichino-Bizzacchi, Association between estrogen receptor alpha and beta gene polymorphisms and deep vein thrombosis, Thromb. Res. 120 (2007) 639–645. [96] A. Bechlioulis, K.K. Naka, S.N. Kalantaridou, A. Chatzikyriakidou, O. Papanikolaou, A. Kaponis, et al., Short-term hormone therapy improves sCD40L and endothelial function in early menopausal women: potential role of estrogen receptor polymorphisms, Maturitas 71 (2012) 389–395. [97] C. Chen, Y. Li, F. Chen, H. Pan, H. Shen, Z. Sun, et al., Estrogen receptor beta genetic variants and combined oral contraceptive use as relates to the risk of hypertension in Chinese women, Arch. Med. Res. 41 (2010) 599–605. [98] J.J. Ashworth, J.V. Smyth, N. Pendleton, M. Horan, A. Payton, J. Worthington, et al., Polymorphisms spanning the 0N exon and promoter of the estrogen receptor-beta (ER(beta)) gene ESR2 are associated with venous ulceration, Clin. Genet. 73 (2008) 55–61. [99] H. Marini, M. Curro, E.B. Adamo, F. Polito, N. Ferlazzo, A. Bitto, et al., The ESR2 AluI 1730G>A (rs4986938) gene polymorphism is associated with fibrinogen plasma levels in postmenopausal women, Gene 508 (2012) 206–210.\n[100] S. Ogawa, M. Emi, M. Shiraki, T. Hosoi, Y. Ouchi, S. Inoue, Association of estrogen receptor (beta) (ESR2) gene polymorphism with blood pressure, J. Hum. Genet. 45 (2000) 327–330. [101] I. Peter, A. Kelley-Hedgepeth, G.S. Huggins, D.E. Housman, M.E. Mendelsohn, J.A. Vita, et al., Association between arterial stiffness and variations in oestrogen-related genes, J. Hum. Hypertens. 23 (2009) 636–644. [102] H.P. Yu, T. Shimizu, Y.C. Hsieh, T. Suzuki, M.A. Choudhry, M.G. Schwacha, et al., Tissue-specific expression of estrogen receptors and their role in the regulation of neutrophil infiltration in various organs following trauma–hemorrhage, J. Leukoc. Biol. 79 (2006) 963–970. [103] W.R. Harrington, S. Sheng, D.H. Barnett, L.N. Petz, J.A. Katzenellenbogen, B.S. Katzenellenbogen, Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression, Mol. Cell. Endocrinol. 206 (2003) 13–22. [104] S. Domingues-Montanari, I. Subirana, M. Tomas, J. Marrugat, M. Senti, Association between ESR2 genetic variants and risk of myocardial infarction, Clin. Chem. 54 (2008) 1183–1189. [105] M. Reimann, K. Vafeiadou, W.L. Hall, J. Dierkes, M. Nilsson, K. Dahlman-Wright, et al., Evidence for associations between common polymorphisms of estrogen receptor (beta) gene with homocysteine and nitric oxide, Climacteric 9 (2006) 215–223. [106] I. Peter, A.M. Shearman, R.S. Vasan, D.R. Zucker, C.H. Schmid, S. Demissie, et al., Association of estrogen receptor (beta) gene polymorphisms with left ventricular mass and wall thickness in women, Am. J. Hypertens. 18 (2005) 1388–1395. [107] M. Darabi, M. Ani, M. Panjehpour, M. Rabbani, A. Movahedian, E. Zarean, Effect of estrogen receptor (beta) A1730G polymorphism on ABCA1 gene expression response to postmenopausal hormone replacement therapy, Gent. Test Mol. Biomarkers 15 (2011) 11–15. [108] K.M. Rexrode, P.M. Ridker, H.H. Hegener, J.E. Buring, J.E. Manson, R.Y.L. Zee, Polymorphisms and haplotypes of the estrogen receptor-(beta) gene (ESR2) and cardiovascular disease in men and women, Clin. Chem. 53 (2007) 1749–1756. [109] N.P. Tobin, J.C. Harrell, J. Lovrot, S. Egyhazi Brage, M. Frostvik Stolt, L. Carlsson, et al., Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival, Ann. Oncol. 26 (2015) 81–88. [110] M. Ghosh, S.J. Brancato, P.K. Agarwal, A.B. Apolo, Targeted therapies in urothelial carcinoma, Curr. Opin. Oncol. 26 (2014) 305–320. [111] K. Romer, M. Pfreundschuh, How do estrogens control lymphoma? (vol 123, pg 1980, 2014), Blood 124 (2014) 1695. [112] T.C. Foster, Role of estrogen receptor alpha and beta expression and signaling on cognitive function during aging, Hippocampus 22 (2012) 656–669. [113] W.S. Post, P.J. Goldschmidt-Clermont, C.C. Wilhide, A.W. Heldman, M.S. Sussman, P. Ouyang, et al., Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system, Cardiovasc. Res. 43 (1999) 985–991. [114] L. Novensa, S. Novella, P. Medina, G. Segarra, N. Castillo, M. Heras, et al., Aging negatively affects estrogens-mediated effects on nitric oxide\nbioavailability by shifting ERalpha/ERbeta balance in female mice, PLoS One 6 (2011), e25335.\n[115] A. Maggi, A. Cignarella, A. Brusadelli, C. Bolego, C. Pinna, L. Puglisi, Diabetes undermines estrogen control of inducible nitric oxide synthase function in\nturitas\n[\n[\n[\n[\n[\n[\n[\n[\nvascular smooth muscle cells, Arterioscler. Thromb. Vasc. Biol. 33 (2013) 257–265.\n[128] K.W. Leung, F.P. Leung, N.K. Mak, J. Tombran-Tink, Y. Huang, R.N. Wong, Protopanaxadiol and protopanaxatriol bind to glucocorticoid and oestrogen receptors in endothelial cells, Br. J. Pharmacol. 156 (2009) 626–637.\nT. Muka et al. / Ma\nrat aortic smooth muscle cells through overexpression of estrogen receptor-beta, Circulation 108 (2003) 211–217.\n116] H.A. Harris, Estrogen receptor-beta: recent lessons from in vivo studies, Mol. Endocrinol. 21 (2007) 1–13. 117] M.C. Antal, A. Krust, P. Chambon, M. Mark, Sterility and absence of histopathological defects in nonreproductive organs of a mouse ERbeta-null mutant, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 2433–2438. 118] J.F. Arnal, C. Fontaine, A. Billon-Gales, J. Favre, H. Laurell, F. Lenfant, et al., Estrogen receptors and endothelium, Arterioscler. Thromb. Vasc. Biol. 30 (2010) 1506–1512. 119] M.R. Meyer, M. Barton, ERalpha, ERbeta, and gpER: novel aspects of oestrogen receptor signalling in atherosclerosis, Cardiovasc. Res. 83 (2009) 605–610. 120] M.Y. Farhat, M.C. Lavigne, P.W. Ramwell, The vascular protective effects of estrogen, FASEB J. 10 (1996) 615–624. 121] R. Addis, I. Campesi, M. Fois, G. Capobianco, S. Dessole, G. Fenu, et al., Human umbilical endothelial cells (HUVECs) have a sex: characterisation of the phenotype of male and female cells, Biol. Sex Differ. 5 (1) (2014) 18. 122] M. Chen, F. Xiong, L. Zhang, Promoter methylation of Egr-1 site contributes to fetal hypoxia-mediated PKC(epsilon) gene repression in the developing\nheart, Am. J. Physiol. Regul. Integr. Comp. Physiol. 304 (2013) R683–R689.\n123] G. Douglas, M.N. Cruz, L. Poston, J.A. Gustafsson, K. Kublickiene, Functional characterization and sex differences in small mesenteric arteries of the estrogen receptor-(beta) knockout mouse, Am. J. Physiol. Regul. Integr. Comp. Physiol. 294 (2008) R112–R120.\n86 (2016) 28–43 43\n[124] Y. Ma, X. Qiao, A.E. Falone, O.M. Reslan, S.J. Sheppard, R.A. Khalil, Gender-specific reduction in contraction is associated with increased estrogen receptor expression in single vascular smooth muscle cells of female rat, Cell. Physiol. Biochem. 26 (2010) 457–470. [125] R.G. Mishra, F.Z. Stanczyk, K.A. Burry, S. Oparil, B.S. Katzenellenbogen, M.L. Nealen, et al., Metabolite ligands of estrogen receptor-(beta) reduce primate coronary hyperreactivity, Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H295–H303. [126] M. Wang, Y. Wang, B. Weil, A. Abarbanell, J. Herrmann, J. Tan, et al., Estrogen receptor (beta) mediates increased activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia, Am. J. Physiol. Regul. Integr. Comp. Physiol. 296 (2009) R972–R978. [127] J. Zhao, G.A. Imbrie, W.E. Baur, L.K. Iyer, M.J. Aronovitz, T.B. Kershaw, et al., Estrogen receptor-mediated regulation of MicroRNA inhibits proliferation of"
    } ],
    "references" : [ {
      "title" : "Global burden of cardiovascular diseases: part I: general considerations",
      "author" : [ "S. Yusuf", "S. Reddy", "S. Ounpuu", "S. Anand" ],
      "venue" : "the epidemiologic transition, risk factors, and impact of urbanization, Circulation 104 ",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "Increased risk of atherosclerosis in women after the menopause",
      "author" : [ "J.C. Witteman", "D.E. Grobbee", "F.J. Kok", "A. Hofman", "H.A. Valkenburg" ],
      "venue" : "BMJ 298 ",
      "citeRegEx" : "2",
      "shortCiteRegEx" : null,
      "year" : 1989
    }, {
      "title" : "Estrogen",
      "author" : [ "X.P. Yang", "J.F. Reckelhoff" ],
      "venue" : "hormonal replacement therapy and cardiovascular disease, Curr. Opin. Nephrol. Hypertens. 20 ",
      "citeRegEx" : "3",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Brief report: coronary heart disease events associated with hormone therapy in younger and older women",
      "author" : [ "S.R. Salpeter", "J.M. Walsh", "E. Greyber", "E.E. Salpeter" ],
      "venue" : "A meta-analysis, J. Gen. Intern. Med. 21 ",
      "citeRegEx" : "4",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "D",
      "author" : [ "J.E. Rossouw", "R.L. Prentice", "J.E. Manson", "L. Wu" ],
      "venue" : "Barad, V.M. Barnabei, et al., Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause, JAMA 297 ",
      "citeRegEx" : "5",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits",
      "author" : [ "M. Barton", "M.R. Meyer", "E. Haas" ],
      "venue" : "Arterioscler. Thromb. Vasc. Biol. 27 ",
      "citeRegEx" : "6",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy",
      "author" : [ "K.K. Koh" ],
      "venue" : "Int. J. Cardiol. 87 ",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Estrogen signaling and cardiovascular disease",
      "author" : [ "E. Murphy" ],
      "venue" : "Circ. Res. 109 ",
      "citeRegEx" : "8",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "A",
      "author" : [ "E. Dworatzek", "S. Mahmoodzadeh", "C. Schubert", "C. Westphal", "J. Leber" ],
      "venue" : "Kusch, et al., Sex differences in exercise-induced physiological myocardial hypertrophy are modulated by oestrogen receptor beta, Cardiovasc. Res. 102 ",
      "citeRegEx" : "9",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload",
      "author" : [ "D Fliegner", "C Schubert", "A Penkalla", "H Witt", "G Kararigas", "E Dworatzek" ],
      "venue" : "[Erratum appears in Am J Physiol Regul Integr Comp Physiol",
      "citeRegEx" : "10",
      "shortCiteRegEx" : "10",
      "year" : 2010
    }, {
      "title" : "U",
      "author" : [ "D. Gurgen", "B. Hegner", "A. Kusch", "R. Catar", "L. Chaykovska" ],
      "venue" : "Hoff, et al., Estrogen receptor-(beta) signals left ventricular hypertrophy sex differences in normotensive deoxycorticosterone acetate-salt mice, Hypertension 57 ",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "The acute relaxant effects of estrogen receptor agonists in diabetic-ovariectomized rat aorta",
      "author" : [ "T. Akhayeva", "N. Ari", "G. Ozansoy" ],
      "venue" : "Turk. J. Pharm. Sci. 8 ",
      "citeRegEx" : "12",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Estrogen receptor-mediated enhancement of venous relaxation in female rat: implications in sex-related differences in varicose veins",
      "author" : [ "J.D. Raffetto", "X. Qiao", "K.G. Beauregard", "R.A. Khalil" ],
      "venue" : "J. Vasc. Surg. 51 ",
      "citeRegEx" : "13",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Relaxations to oestrogen receptor subtype selective agonists in rat and mouse arteries",
      "author" : [ "K. Al Zubair", "A. Razak", "S. Bexis", "J.R. Docherty" ],
      "venue" : "Eur. J. Pharmacol. 513 ",
      "citeRegEx" : "14",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Y",
      "author" : [ "S. Jesmin", "C.N. Mowa", "S.N. Sultana", "N. Shimojo", "H. Togashi" ],
      "venue" : "Iwashima, et al., VEGF signaling is disrupted in the hearts of mice lacking estrogen receptor alpha, Eur. J. Pharmacol. 641 ",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "R",
      "author" : [ "T. Traupe", "C.D. Stettler", "H. Li", "E. Haas", "I. Bhattacharya" ],
      "venue" : "Minotti, et al., Distinct roles of estrogen receptors (alpha) and (beta) mediating acute vasodilation of epicardial coronary arteries, Hypertension 49 ",
      "citeRegEx" : "16",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "The selective estrogen receptor-(beta) agonist biochanin A  turitas  T",
      "author" : [ "S. Schrepfer", "T. Deuse", "T. Munzel", "H. Schafer", "W. Braendle", "H. Reichenspurner" ],
      "venue" : "Muka et al. / Ma shows vasculoprotective effects without uterotrophic activity, Menopause 13 ",
      "citeRegEx" : "17",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "The role of peroxisome proliferator-activated receptor-(gamma) and estrogen receptors in genistein-induced regulation of vascular tone in female rat aortas",
      "author" : [ "Q. Xiang", "G. Lin", "X. Fu", "S. Wang", "T. Wang" ],
      "venue" : "Pharmacology 86 ",
      "citeRegEx" : "18",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "M",
      "author" : [ "J.J. Corcoran", "C. Nicholson", "M. Sweeney", "J.C. Charnock", "S.C. Robson" ],
      "venue" : "Westwood, et al., Human uterine and placental arteries exhibit tissue-specific acute responses to 17(beta)-estradiol and estrogen-receptor-specific agonists, Mol. Hum. Reprod. 20 ",
      "citeRegEx" : "19",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Distinct role of estrogen receptor-alpha and beta on postmenopausal diabetes-induced vascular dysfunction",
      "author" : [ "S. Bansal", "K. Chopra" ],
      "venue" : "Gen. Comp. Endocrinol. ",
      "citeRegEx" : "20",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "L",
      "author" : [ "C. Bolego", "A. Cignarella", "P. Sanvito", "V. Pelosi", "F. Pellegatta" ],
      "venue" : "Puglisi, et al., The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-(alpha) agonists and is abolished by estrogen deprivation, J. Pharmacol. Exp. Ther. 313 ",
      "citeRegEx" : "21",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Subtype-specific estrogen receptor-mediated vasodilator activity in the cephalic",
      "author" : [ "O.M. Reslan", "Z. Yin", "G.R.A. Do Nascimento", "R.A. Khalil" ],
      "venue" : "thoracic, and abdominal vasculature of female rat, J. Cardiovasc. Pharmacol. 62 ",
      "citeRegEx" : "22",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "J",
      "author" : [ "B. Darblade", "C. Pendaries", "A. Krust", "S. Dupont", "M.J. Fouque" ],
      "venue" : "Rami, et al., Estradiol alters nitric oxide production in the mouse aorta through the (alpha)-, but not (beta)-, estrogen receptor, Circ. Res. 90 ",
      "citeRegEx" : "23",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "The oestrogen receptor (beta) contributes to sex related differences in endothelial function of murine small arteries via EDHF",
      "author" : [ "L. Luksha", "L. Poston", "J.A. Gustafsson", "K. Hultenby", "K. Kublickiene" ],
      "venue" : "J. Physiol. 577 ",
      "citeRegEx" : "24",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Increased magnitude of relaxation to oestrogen in aorta from oestrogen receptor (beta) knock-out mice",
      "author" : [ "B.O. Nilsson", "E. Ekblad", "T. Heine", "J.A. Gustafsson" ],
      "venue" : "J. Endocrinol. 166 ",
      "citeRegEx" : "25",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors (alpha) and (beta)",
      "author" : [ "X. Guo", "M. Razandi", "A. Pedram", "G. Kassab", "E.R. Levin" ],
      "venue" : "J. Biol. Chem. 280 ",
      "citeRegEx" : "26",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Dilatory responses to estrogenic compounds in small femoral arteries of male and female estrogen receptor-(beta) knockout mice",
      "author" : [ "M.N. Cruz", "G. Douglas", "J.A. Gustafsson", "L. Poston", "K. Kublickiene" ],
      "venue" : "Am. J. Physiol. Heart Circ. Physiol. 290 ",
      "citeRegEx" : "27",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "R",
      "author" : [ "S. Nuedling", "R.H. Karas", "M.E. Mendelsohn", "J.A. Katzenellenbogen", "B.S. Katzenellenbogen" ],
      "venue" : "Meyer, et al., Activation of estrogen receptor (beta) is a prerequisite for estrogen-dependent upregulation of nitric oxide synthases in neonatal rat cardiac myocytes, FEBS Lett. 502 ",
      "citeRegEx" : "28",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "S",
      "author" : [ "S. Jesmin", "C.N. Mowa", "S.N. Sultana", "S. Mia", "R. Islam" ],
      "venue" : "Zaedi, et al., Estrogen receptor alpha and beta are both involved in the cerebral VEGF/Akt/NO pathway and cerebral angiogenesis in female mice, Biomed. Res. (Japan) 31 ",
      "citeRegEx" : "29",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury",
      "author" : [ "S.A. Gabel", "V.R. Walker", "R.E. London", "C. Steenbergen", "K.S. Korach", "E. Murphy" ],
      "venue" : "J. Mol. Cell. Cardiol. 38 ",
      "citeRegEx" : "30",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "17(beta)-Estradiol induces protein S-nitrosylation in the endothelium",
      "author" : [ "S. Chakrabarti", "O. Lekontseva", "A. Peters", "S.T. Davidge" ],
      "venue" : "Cardiovasc. Res. 85 ",
      "citeRegEx" : "31",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "D",
      "author" : [ "M. Sitges", "A. Leivas", "M. Heras", "E. Ferrer", "M. Roque" ],
      "venue" : "Viles, et al., Short-term transdermal estradiol enhances nitric oxide synthase III and estrogen receptor mRNA expression in arteries of women with coronary artery disease, Int. J. Cardiol. 105 ",
      "citeRegEx" : "32",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "C",
      "author" : [ "S. Novella", "A. Laguna-Fernandez", "M. Lazaro-Franco", "A. Sobrino" ],
      "venue" : "Bueno-Beti, J.J. Tarin, et al., Estradiol, acting through estrogen receptor alpha, restores dimethylarginine dimethylaminohydrolase activity and nitric oxide production in oxLDL-treated human arterial endothelial cells, Mol. Cell. Endocrinol. 365 ",
      "citeRegEx" : "33",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "C",
      "author" : [ "T. Simoncini", "L. Fornari", "P. Mannella", "A. Caruso", "S. Garibaldi" ],
      "venue" : "Baldacci, et al., Activation of nitric oxide synthesis in human endothelial cells by red clover extracts, Menopause 12 ",
      "citeRegEx" : "34",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "S",
      "author" : [ "A.H. Eid", "K. Maiti", "S. Mitra", "M.A. Chotani" ],
      "venue" : "Flavahan, S.R. Bailey, et al., Estrogen increases smooth muscle expression of (alpha) 2C-adrenoceptors and cold-induced constriction of cutaneous arteries, Am. J. Physiol. Heart Circ. Physiol. 293 ",
      "citeRegEx" : "35",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Medical Physiology: A Cellular and Molecular Approach",
      "author" : [ "F.W. Boron" ],
      "venue" : null,
      "citeRegEx" : "36",
      "shortCiteRegEx" : "36",
      "year" : 2012
    }, {
      "title" : "Coronary vasoconstriction mediated by alpha-1-adrenoceptors and alpha-2-adrenoceptors in conscious dogs",
      "author" : [ "O.L. Woodman", "S.F. Vatner" ],
      "venue" : "Am. J. Physiol. 253 ",
      "citeRegEx" : "38",
      "shortCiteRegEx" : null,
      "year" : 1987
    }, {
      "title" : "Gender-specific alteration of adrenergic responses in small femoral arteries from estrogen receptor-(beta) knockout mice",
      "author" : [ "L. Luksha", "L. Poston", "J.A. Gustafsson", "L. Aghajanova", "K. Kublickiene" ],
      "venue" : "Hypertension 46 ",
      "citeRegEx" : "39",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "C",
      "author" : [ "V. Jazbutyte", "P.A. Arias-Loza", "K. Hu", "J. Widder", "V. Govindaraj" ],
      "venue" : "Von Poser-Klein, et al., Ligand-dependent activation of ER(beta) lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats, Cardiovasc. Res. 77 ",
      "citeRegEx" : "40",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "V",
      "author" : [ "P.A. Arias-Loza", "K. Hu", "C. Dienesch", "A.M. Mehlich", "S. Konig" ],
      "venue" : "Jazbutyte, et al., Both estrogen receptor subtypes, (alpha) and (beta), attenuate  86 (2016) 28–43  41 cardiovascular remodeling in aldosterone salt-treated rats, Hypertension 50 ",
      "citeRegEx" : "41",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Activation of estrogen receptor-(alpha) protects the in vivo rabbit heart from ischemia-reperfusion injury",
      "author" : [ "E.A. Booth", "N.R. Obeid", "B.R. Lucchesi" ],
      "venue" : "Am. J. Physiol. Heart Circ. Physiol. 289 ",
      "citeRegEx" : "42",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "L",
      "author" : [ "T. Pelzer", "P.A.A. Loza", "K. Hu", "B. Bayer", "C. Dienesch" ],
      "venue" : "Calvillo, et al., Increased mortality and aggravation of heart failure in estrogen receptor-(beta) knockout mice after myocardial infarction, Circulation 111 ",
      "citeRegEx" : "43",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Involvement of estrogen receptor-B in farrerol inhibition of rat thoracic aorta vascular smooth muscle cell proliferation",
      "author" : [ "Q.Y. Li", "L. Chen", "Y.H. Zhu", "M. Zhang", "Y.P. Wang", "M.W. Wang" ],
      "venue" : "Acta Pharmacol. Sin. 32 ",
      "citeRegEx" : "44",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "R",
      "author" : [ "I. Baruscotti", "F. Barchiesi", "E.K. Jackson", "B. Imthurn" ],
      "venue" : "Stiller, J.H. Kim, et al., Estradiol stimulates capillary formation by human endothelial progenitor cells: Role of estrogen receptor-(alpha)/(beta), heme oxygenase 1, and tyrosine kinase, Hypertension 56 ",
      "citeRegEx" : "45",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "M",
      "author" : [ "A. Giddabasappa", "J.R. Eswaraka", "C.M. Barrett", "M.N. Bauler", "Z. Wu" ],
      "venue" : "Yepuru, et al., (beta)-LGND2, an ER(beta) selective agonist, inhibits pathologic retinal neovascularization, Invest. Ophthalmol. Vis. Sci. 53 ",
      "citeRegEx" : "46",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "ER(beta)-dependent effects on uterine endothelial cells are cell specific and mediated via Sp1",
      "author" : [ "E. Greaves", "F. Collins", "H.O.D. Critchley", "P.T.K. Saunders" ],
      "venue" : "Hum. Reprod. 28 ",
      "citeRegEx" : "47",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Ginsenoside Rb1 inhibits tube-like structure formation of endothelial cells by regulating pigment epithelium-derived factor through the oestrogen (beta) receptor, Br",
      "author" : [ "K.W. Leung", "L.W.T. Cheung", "Y.L. Pon", "R.N.S. Wong", "N.K. Mak", "T.P.P. Fan" ],
      "venue" : "J. Pharmacol",
      "citeRegEx" : "48",
      "shortCiteRegEx" : "48",
      "year" : 2007
    }, {
      "title" : "E",
      "author" : [ "A.M. Broberg", "A.J. Siddiqui", "H. Fischer", "K.H. Grinnemo" ],
      "venue" : "Wardell, A.B. Andersson, et al., Estrogen receptors do not influence angiogenesis after myocardial infarction, Scand. Cardiovasc. J. 45 ",
      "citeRegEx" : "49",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Stimulation of vascular protein synthesis by activation of oestrogen receptor (beta)",
      "author" : [ "M. Liang", "E. Ekblad", "J.A. Gustafsson", "B.O. Nilsson" ],
      "venue" : "J. Endocrinol. 171 ",
      "citeRegEx" : "50",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "G",
      "author" : [ "H. Hamada", "M.K. Kim", "A. Iwakura", "M. Ii", "T. Thorne" ],
      "venue" : "Qin, et al., Estrogen receptors (alpha) and (beta) mediate contribution of bone marrow-derived endothelial progenitor cells to functional recovery after myocardial infarction, Circulation 114 ",
      "citeRegEx" : "51",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-(alpha) but not estrogen receptor-(beta)",
      "author" : [ "L. Brouchet", "A. Krust", "S. Dupont", "P. Chambon", "F. Bayard", "J.F. Arnal" ],
      "venue" : "Circulation 103 ",
      "citeRegEx" : "52",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "Activation of estrogen receptor (beta) reduces blood–brain barrier breakdown following ischemic injury",
      "author" : [ "J.A. Shin", "S.J. Yang", "S.I. Jeong", "H.J. Park", "Y.H. Choi", "E.M. Park" ],
      "venue" : "Neuroscience 235 ",
      "citeRegEx" : "53",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Estrogen-responsive nitroso-proteome in uterine artery endothelial cells: role of endothelial nitric oxide synthase and estrogen receptor-(beta)",
      "author" : [ "H.H. Zhang", "L. Feng", "W. Wang", "R.R. Magness", "D.B. Chen" ],
      "venue" : "J. Cell. Physiol. 227 ",
      "citeRegEx" : "54",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Claudin-5 as a novel estrogen target in vascular endothelium",
      "author" : [ "M. Burek", "P.A. Arias-Loza", "N. Roewer", "C.Y. Forster" ],
      "venue" : "Arterioscler. Thromb. Vasc. Biol. 30 ",
      "citeRegEx" : "55",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Mechanisms of transcriptional activation of the mouse claudin-5 promoter by estrogen receptor alpha and beta",
      "author" : [ "M. Burek", "K. Steinberg", "C.Y. Forster" ],
      "venue" : "Mol. Cell. Endocrinol. 392 ",
      "citeRegEx" : "56",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "S",
      "author" : [ "E.J. Su", "Z.H. Lin", "R. Zeine", "P. Yin" ],
      "venue" : "Reierstad, J.E. Innes, et al., Estrogen receptor-beta mediates cyclooxygenase-2 expression and vascular prostanoid levels in human placental villous endothelial cells, Am. J. Obstet. Gynecol. 200 (427) ",
      "citeRegEx" : "57",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Vascular smooth muscle cell motility: from migration to invasion",
      "author" : [ "S.F. Louis", "P. Zahradka" ],
      "venue" : "Exp. Clin. Cardiol. 15 ",
      "citeRegEx" : "58",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Inhibition of lymphoma vascularization and dissemination by estrogen receptor beta agonists",
      "author" : [ "K. Yakimchuk", "M.S. Hasni", "J. Guan", "M.P. Chao", "B. Sander", "S. Okret" ],
      "venue" : "Blood 123 ",
      "citeRegEx" : "59",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "C",
      "author" : [ "B. Cheng", "J. Song", "Y. Zou", "Q. Wang", "Y. Lei" ],
      "venue" : "Zhu, et al., Responses of vascular smooth muscle cells to estrogen are dependent on balance between ERK and p38 MAPK pathway activities, Int. J. Cardiol. 134 ",
      "citeRegEx" : "60",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "E",
      "author" : [ "S. Makela", "H. Savolainen", "E. Aavik", "M. Myllarniemi", "L. Strauss" ],
      "venue" : "Taskinen, et al., Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors (alpha) and (beta), Proc. Natl. Acad. Sci. U. S. A. 96 ",
      "citeRegEx" : "61",
      "shortCiteRegEx" : null,
      "year" : 1999
    }, {
      "title" : "F",
      "author" : [ "M. Pellegrini", "P. Bulzomi", "M. Lecis", "S. Leone", "I. Campesi" ],
      "venue" : "Franconi, et al., Endocrine disruptors differently influence estrogen receptor (beta) and androgen receptor in male and female rat VSMC, J. Cell. Physiol. 229 ",
      "citeRegEx" : "62",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Q",
      "author" : [ "M.E. Hogg", "A.K. Vavra", "M.N. Banerjee", "J. Martinez" ],
      "venue" : "Jiang, L.K. Keefer, et al., The role of estrogen receptor (alpha) and (beta) in regulating vascular smooth muscle cell proliferation is based on sex, J. Surg. Res. 173 ",
      "citeRegEx" : "63",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Z",
      "author" : [ "J. Ortmann", "M. Veit", "S. Zingg", "S. Di Santo", "T. Traupe" ],
      "venue" : "Yang, et al., Estrogen receptor-(alpha) but not -(beta) or GPER inhibits high glucose-induced human VSMC proliferation: potential role of ROS and ERK, J. Clin. Endocrinol. Metab. 96 ",
      "citeRegEx" : "64",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Multiple mechanisms of soy isoflavones against oxidative stress-induced endothelium injury",
      "author" : [ "S.Z. Xu", "W. Zhong", "M. Ghavideldarestani", "R. Saurabh", "S.W. Lindow", "S.L. Atkin" ],
      "venue" : "Free Radic. Biol. Med. 47 ",
      "citeRegEx" : "65",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "T",
      "author" : [ "Y. Nakamura", "T. Suzuki", "Y. Miki", "C. Tazawa", "K. Senzaki" ],
      "venue" : "Moriya, et al., Estrogen receptors in atherosclerotic human aorta: inhibition of human  4  turitas  2  T. Muka et al. / Ma vascular smooth muscle cell proliferation by estrogens, Mol. Cell.Endocrinol. 219 ",
      "citeRegEx" : "66",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "L",
      "author" : [ "D. Xing", "W. Feng", "A.P. Miller", "N.M. Weathington", "Y.F. Chen" ],
      "venue" : "Novak, et al., Estrogen modulates TNF-(alpha)-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-(beta) activation, Am. J. Physiol. Heart Circ. Physiol. 292 ",
      "citeRegEx" : "67",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "J",
      "author" : [ "D. Xing", "S. Oparil", "H. Yu", "K. Gong", "W. Feng" ],
      "venue" : "Black, et al., Estrogen modulates NF(kappa)B signaling by enhancing I(kappa)B(alpha) levels and blocking p65 binding at the promoters of inflammatory genes via estrogen receptor-(beta), PLoS One 7 (6) ",
      "citeRegEx" : "68",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Estradiol-17(beta) and its cytochrome P450-and catechol-Omethyltransferase-derived metabolites stimulate proliferation in uterine artery endothelial cells: role of estrogen receptor-(alpha) versus estrogen receptor-(beta)",
      "author" : [ "S.O. Jobe", "J. Ramadoss", "J.M. Koch", "Y. Jiang", "J. Zheng", "R.R. Magness" ],
      "venue" : "Hypertension 55 ",
      "citeRegEx" : "69",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Membrane ER(alpha) attenuates myocardial fibrosis via RhoA/ROCK-mediated actin remodeling in ovariectomized female infarcted rats",
      "author" : [ "T.M. Lee", "S.Z. Lin", "N.C. Chang" ],
      "venue" : "J. Mol. Med. 92 ",
      "citeRegEx" : "70",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Apoptosis in the cardiovascular system",
      "author" : [ "M.R. Bennett" ],
      "venue" : "Heart 87 ",
      "citeRegEx" : "71",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "Molecular mechanisms underlying the rapid arrhythmogenic action of bisphenol A in female rat hearts",
      "author" : [ "X. Gao", "Q. Liang", "Y. Chen", "H.S. Wang" ],
      "venue" : "Endocrinology 154 ",
      "citeRegEx" : "72",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "R",
      "author" : [ "I.A. Sebag", "M.A. Gillis", "A. Calderone", "A. Kasneci", "M. Meilleur" ],
      "venue" : "Haddad, et al., Sex hormone control of left ventricular structure/function: mechanistic insights using echocardiography, expression, and DNA methylation analyses in adult mice, Am. J. Physiol. Heart Circ. Physiol. 301 ",
      "citeRegEx" : "73",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "R",
      "author" : [ "F.A. Babiker", "D. Lips" ],
      "venue" : "Meyer, et al., Estrogen receptor beta protects the murine heart against left ventricular hypertrophy, Arterioscler. Thromb. Vasc. Biol. 26 (7) ",
      "citeRegEx" : "74",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "C",
      "author" : [ "G. Kararigas", "D. Fliegner", "S. Forler", "O. Klein" ],
      "venue" : "Schubert, J.A. Gustafsson, et al., Comparative proteomic analysis reveals sex and estrogen receptor beta effects in the pressure overloaded heart, J. Proteome Res. 13 (12) ",
      "citeRegEx" : "75",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Role of the estrogen/estrogen-receptor-beta axis in the genomic response to pressure overload-induced hypertrophy",
      "author" : [ "G. Kararigas", "D. Fliegner", "J.A. Gustafsson", "V. Regitz-Zagrosek" ],
      "venue" : "Physiol. Genomics. 43 ",
      "citeRegEx" : "76",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Estrogen-enhanced gene expression of lipoprotein lipase in heart is antagonized by progesterone",
      "author" : [ "D. Liu", "A. Deschamps", "K.S. Korach", "E. Murphy" ],
      "venue" : "Endocrinology 149 ",
      "citeRegEx" : "77",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Treatment with an estrogen receptor-beta-selective agonist is cardioprotective",
      "author" : [ "I. Nikolic", "D. Liu", "J.A. Bell", "J. Collins", "C. Steenbergen", "E. Murphy" ],
      "venue" : "J. Mol. Cell. Cardiol. 42 ",
      "citeRegEx" : "78",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Y",
      "author" : [ "M. Otsuki", "H. Gao", "K. Dahlman-Wright", "C. Ohlsson", "N. Eguchi" ],
      "venue" : "Urade, et al., Specific regulation of lipocalin-type prostaglandin D synthase in mouse heart by estrogen receptor (beta), Mol. Endocrinol. 17 ",
      "citeRegEx" : "79",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Dennis Lubahn",
      "author" : [ "A. Pedram", "M. Razandi", "F.O. Mahony" ],
      "venue" : "R. Ellis Levin, Estrogen receptor- prevents cardiac fibrosis, Mol. Endocrinol. 24 (11) ",
      "citeRegEx" : "80",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Estrogen regulates histone deacetylases to prevent cardiac hypertrophy",
      "author" : [ "A. Pedrama", "M. Razandi", "R. Narayanan", "J.T. Dalton", "T.A. McKinsey", "E.R. Levin" ],
      "venue" : "Mol. Biol. Cell. 24 ",
      "citeRegEx" : "81",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "C",
      "author" : [ "A.M. Queiros", "C. Eschen", "D. Fliegner", "G. Kararigas", "E. Dworatzek" ],
      "venue" : "Westphal, et al., Sex- and estrogen-dependent regulation of a miRNA network in the healthy and hypertrophied heart, Int. J. Cardiol. 169 ",
      "citeRegEx" : "82",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "L",
      "author" : [ "M. Skavdahl", "C. Steenbergen", "J. Clark", "P. Myers", "T. Demianenko" ],
      "venue" : "Mao, et al., Estrogen receptor-(beta) mediates male-female differences in the development of pressure overload hypertrophy, Am. J. Physiol. Heart Circ. Physiol. 288 ",
      "citeRegEx" : "83",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Estrogen receptor beta mediates acute myocardial protection following ischemia",
      "author" : [ "M. Wang", "P.R. Crisostomo", "T. Markel", "Y. Wang", "K.D. Lillemoe", "D.R. Meldrum" ],
      "venue" : "Surgery (USA) 144 ",
      "citeRegEx" : "84",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "X",
      "author" : [ "K. Rayner", "J. Sun", "Y.X. Chen", "M. McNulty", "T. Simard" ],
      "venue" : "Zhao, et al., Heat shock protein 27 protects against atherogenesis via an estrogen-dependent mechanism: role of selective estrogen receptor beta modulation, Arterioscler. Thromb. Vasc. Biol. 29 ",
      "citeRegEx" : "85",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Studies on estrogen receptor (ER) (alpha) and (beta) responses on gene regulation in peripheral blood leukocytes in vivo using selective ER agonists",
      "author" : [ "D. Stygar", "B. Masironi", "H. Eriksson", "L. Sahlin" ],
      "venue" : "J. Endocrinol. 194 ",
      "citeRegEx" : "86",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "R",
      "author" : [ "Y.C. Wang", "X.L. Xiao", "N. Li", "D. Yang", "Y. Xing" ],
      "venue" : "Huo, et al., Oestrogen inhibits BMP4-induced BMP4 expression in cardiomyocytes: a potential mechanism of oestrogen-mediated protection against cardiac hypertrophy, Br. J. Pharmacol. ",
      "citeRegEx" : "87",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Estrogen receptors (alpha) and (beta) mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen",
      "author" : [ "R. O’Lone", "K. Knorr", "I.Z. Jaffe", "M.E. Schaffer", "P.G.V. Martini", "R.H. Karas" ],
      "venue" : "species, Mol. Endocrinol",
      "citeRegEx" : "88",
      "shortCiteRegEx" : "88",
      "year" : 2007
    }, {
      "title" : "Estrogen-induced SDF-1 production is mediated by estrogen receptor-(alpha) in female hearts after acute ischemia and reperfusion",
      "author" : [ "C. Huang", "H. Gu", "Y. Wang", "M. Wang" ],
      "venue" : "Surgery (USA) 150 ",
      "citeRegEx" : "89",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "W",
      "author" : [ "B.H. Cong", "Y.J. Xu", "H. Sheng", "X.Y. Zhu", "L. Wang" ],
      "venue" : "Zhao, et al., Cardioprotection of 17 beta-estradiol against hypoxia/reoxygenation in cardiomyocytes is partly through up-regulation of CRH receptor type 2, Mol. Cell. Endocrinol. 382 (2014) 17–25.  86 ",
      "citeRegEx" : "90",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "A",
      "author" : [ "M. Jayachandran", "C.C. Preston", "L.W. Hunter" ],
      "venue" : "Jahangir, W.G. Owen, K.S. Korach, et al., Loss of estrogen receptor (beta) decreases mitochondrial energetic potential and increases thrombogenicity of platelets in aged female mice, Age 32 ",
      "citeRegEx" : "91",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "S",
      "author" : [ "M.R. Bowling", "D. Xing", "A. Kapadia", "Y.F. Chen", "A.J. Szalai" ],
      "venue" : "Oparil, et al., Estrogen effects on vascular inflammation are age dependent: role of estrogen receptors, Arterioscler. Thromb. Vasc. Biol. 34 ",
      "citeRegEx" : "92",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Effects of estrogen on vascular inflammation: a matter of timing",
      "author" : [ "S. Novella", "M. Heras", "C. Hermenegildo", "A.P. Dantas" ],
      "venue" : "Arterioscler. Thromb. Vasc. Biol. 32 ",
      "citeRegEx" : "93",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Intimal estrogen receptor (ER) beta",
      "author" : [ "R.C. Christian", "P.Y. Liu", "S. Harrington", "M. Ruan", "V.M. Miller", "L.A. Fitzpatrick" ],
      "venue" : "but not ERalpha expression, is correlated with coronary calcification and atherosclerosis in pre- and postmenopausal women, J. Clin. Endocrinol. Metab. 91 ",
      "citeRegEx" : "94",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "A",
      "author" : [ "A.M. Alessio", "N.F. Hoehr", "L.H. Siqueira", "M.C. Ozelo" ],
      "venue" : "de Padua Mansur, J.M. Annichino-Bizzacchi, Association between estrogen receptor alpha and beta gene polymorphisms and deep vein thrombosis, Thromb. Res. 120 ",
      "citeRegEx" : "95",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "A",
      "author" : [ "A. Bechlioulis", "K.K. Naka", "S.N. Kalantaridou", "A. Chatzikyriakidou", "O. Papanikolaou" ],
      "venue" : "Kaponis, et al., Short-term hormone therapy improves sCD40L and endothelial function in early menopausal women: potential role of estrogen receptor polymorphisms, Maturitas 71 ",
      "citeRegEx" : "96",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Z",
      "author" : [ "C. Chen", "Y. Li", "F. Chen", "H. Pan", "H. Shen" ],
      "venue" : "Sun, et al., Estrogen receptor beta genetic variants and combined oral contraceptive use as relates to the risk of hypertension in Chinese women, Arch. Med. Res. 41 ",
      "citeRegEx" : "97",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "J",
      "author" : [ "J.J. Ashworth", "J.V. Smyth", "N. Pendleton", "M. Horan", "A. Payton" ],
      "venue" : "Worthington, et al., Polymorphisms spanning the 0N exon and promoter of the estrogen receptor-beta (ER(beta)) gene ESR2 are associated with venous ulceration, Clin. Genet. 73 ",
      "citeRegEx" : "98",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "A",
      "author" : [ "H. Marini", "M. Curro", "E.B. Adamo", "F. Polito", "N. Ferlazzo" ],
      "venue" : "Bitto, et al., The ESR2 AluI 1730G>A (rs4986938) gene polymorphism is associated with fibrinogen plasma levels in postmenopausal women, Gene 508 ",
      "citeRegEx" : "99",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Association of estrogen receptor (beta) (ESR2) gene polymorphism with blood pressure",
      "author" : [ "S. Ogawa", "M. Emi", "M. Shiraki", "T. Hosoi", "Y. Ouchi", "S. Inoue" ],
      "venue" : "J. Hum. Genet. 45 ",
      "citeRegEx" : "100",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "A",
      "author" : [ "I. Peter" ],
      "venue" : "Kelley-Hedgepeth, G.S. Huggins, D.E. Housman, M.E. Mendelsohn, J.A. Vita, et al., Association between arterial stiffness and variations in oestrogen-related genes, J. Hum. Hypertens. 23 ",
      "citeRegEx" : "101",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "T",
      "author" : [ "H.P. Yu", "T. Shimizu", "Y.C. Hsieh" ],
      "venue" : "Suzuki, M.A. Choudhry, M.G. Schwacha, et al., Tissue-specific expression of estrogen receptors and their role in the regulation of neutrophil infiltration in various organs following trauma–hemorrhage, J. Leukoc. Biol. 79 ",
      "citeRegEx" : "102",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression",
      "author" : [ "W.R. Harrington", "S. Sheng", "D.H. Barnett", "L.N. Petz", "J.A. Katzenellenbogen", "B.S. Katzenellenbogen" ],
      "venue" : "Mol. Cell. Endocrinol. 206 ",
      "citeRegEx" : "103",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Association between ESR2 genetic variants and risk of myocardial infarction",
      "author" : [ "S. Domingues-Montanari", "I. Subirana", "M. Tomas", "J. Marrugat", "M. Senti" ],
      "venue" : "Clin. Chem. 54 ",
      "citeRegEx" : "104",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "K",
      "author" : [ "M. Reimann", "K. Vafeiadou", "W.L. Hall", "J. Dierkes", "M. Nilsson" ],
      "venue" : "Dahlman-Wright, et al., Evidence for associations between common polymorphisms of estrogen receptor (beta) gene with homocysteine and nitric oxide, Climacteric 9 ",
      "citeRegEx" : "105",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "S",
      "author" : [ "I. Peter", "A.M. Shearman", "R.S. Vasan", "D.R. Zucker", "C.H. Schmid" ],
      "venue" : "Demissie, et al., Association of estrogen receptor (beta) gene polymorphisms with left ventricular mass and wall thickness in women, Am. J. Hypertens. 18 ",
      "citeRegEx" : "106",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Effect of estrogen receptor (beta) A1730G polymorphism on ABCA1 gene expression response to postmenopausal hormone replacement therapy",
      "author" : [ "M. Darabi", "M. Ani", "M. Panjehpour", "M. Rabbani", "A. Movahedian", "E. Zarean" ],
      "venue" : "Gent. Test Mol. Biomarkers 15 ",
      "citeRegEx" : "107",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Polymorphisms and haplotypes of the estrogen receptor-(beta) gene (ESR2) and cardiovascular disease in men and women",
      "author" : [ "K.M. Rexrode", "P.M. Ridker", "H.H. Hegener", "J.E. Buring", "J.E. Manson", "R.Y.L. Zee" ],
      "venue" : "Clin. Chem. 53 ",
      "citeRegEx" : "108",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "L",
      "author" : [ "N.P. Tobin", "J.C. Harrell", "J. Lovrot", "S. Egyhazi Brage", "M. Frostvik Stolt" ],
      "venue" : "Carlsson, et al., Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival, Ann. Oncol. 26 ",
      "citeRegEx" : "109",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Targeted therapies in urothelial carcinoma",
      "author" : [ "M. Ghosh", "S.J. Brancato", "P.K. Agarwal", "A.B. Apolo" ],
      "venue" : "Curr. Opin. Oncol. 26 ",
      "citeRegEx" : "110",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "How do estrogens control lymphoma? (vol 123",
      "author" : [ "K. Romer", "M. Pfreundschuh" ],
      "venue" : "pg 1980, 2014), Blood 124 ",
      "citeRegEx" : "111",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Role of estrogen receptor alpha and beta expression and signaling on cognitive function during aging",
      "author" : [ "T.C. Foster" ],
      "venue" : "Hippocampus 22 ",
      "citeRegEx" : "112",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "P",
      "author" : [ "W.S. Post", "P.J. Goldschmidt-Clermont", "C.C. Wilhide", "A.W. Heldman", "M.S. Sussman" ],
      "venue" : "Ouyang, et al., Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system, Cardiovasc. Res. 43 ",
      "citeRegEx" : "113",
      "shortCiteRegEx" : null,
      "year" : 1999
    }, {
      "title" : "M",
      "author" : [ "L. Novensa", "S. Novella", "P. Medina", "G. Segarra", "N. Castillo" ],
      "venue" : "Heras, et al., Aging negatively affects estrogens-mediated effects on nitric oxide bioavailability by shifting ERalpha/ERbeta balance in female mice, PLoS One 6 ",
      "citeRegEx" : "114",
      "shortCiteRegEx" : null,
      "year" : 2011
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "Despite improvements in prevention and treatment, cardiovasular disease (CVD) remains the leading cause of death for women orldwide [1].",
      "startOffset" : 132,
      "endOffset" : 135
    }, {
      "referenceID" : 1,
      "context" : "Epidemiological studies have revealed that, comared with age-matched men, premenopausal women have a lower isk of coronary heart disease (CHD) which gradually increases after enopause so that by the sixth decade women have the same incience of CHD as men [2].",
      "startOffset" : 255,
      "endOffset" : 258
    }, {
      "referenceID" : 2,
      "context" : "Extensive evidence from observational studes suggest cardio-protective effects of endogenous and exogenous strogens in premenopausal women [3].",
      "startOffset" : 139,
      "endOffset" : 142
    }, {
      "referenceID" : 3,
      "context" : "Similarly, results from linical trials suggest that estrogen therapy started within the first ears after menopause reduce cardiovascular risk’ [4,5]; whereas nitiation of estrogen therapy many years after menopause may ave no or even deleterious cardiovascular effects [5,6].",
      "startOffset" : 143,
      "endOffset" : 148
    }, {
      "referenceID" : 4,
      "context" : "Similarly, results from linical trials suggest that estrogen therapy started within the first ears after menopause reduce cardiovascular risk’ [4,5]; whereas nitiation of estrogen therapy many years after menopause may ave no or even deleterious cardiovascular effects [5,6].",
      "startOffset" : 143,
      "endOffset" : 148
    }, {
      "referenceID" : 4,
      "context" : "Similarly, results from linical trials suggest that estrogen therapy started within the first ears after menopause reduce cardiovascular risk’ [4,5]; whereas nitiation of estrogen therapy many years after menopause may ave no or even deleterious cardiovascular effects [5,6].",
      "startOffset" : 269,
      "endOffset" : 274
    }, {
      "referenceID" : 5,
      "context" : "Similarly, results from linical trials suggest that estrogen therapy started within the first ears after menopause reduce cardiovascular risk’ [4,5]; whereas nitiation of estrogen therapy many years after menopause may ave no or even deleterious cardiovascular effects [5,6].",
      "startOffset" : 269,
      "endOffset" : 274
    }, {
      "referenceID" : 6,
      "context" : "In line with this ypothesis, it has recently been suggested that favorable vascular ffects of estrogen depend on the endothelium and are mediated ainly via estrogen receptors alpha (ER ) and beta (ER ) [7].",
      "startOffset" : 202,
      "endOffset" : 205
    }, {
      "referenceID" : 7,
      "context" : "herefore, age- and menopause-related endothelial injury, changes n vascular estrogen receptors expression, intracellular signaling r genomics may alter the cardiovascular effects of this sex horone [8].",
      "startOffset" : 198,
      "endOffset" : 201
    }, {
      "referenceID" : 19,
      "context" : "Eight studies (7 animal model studies and 1 human model study) showed that activation of ER via its agonists (diarylpropionitrile (DPN), Biochanin A and Genistein) was associated with increased relaxation of the vessels (thoracic aorta, inferior vena cava, descending coronary artery, aorta, mesenteric artery; and chorionic and myometrial arteries) [12–19], whereas two studies showed no effect of ER on vascular reactivity (thoracic aorta and mesenteric artery) [20,21].",
      "startOffset" : 464,
      "endOffset" : 471
    }, {
      "referenceID" : 20,
      "context" : "Eight studies (7 animal model studies and 1 human model study) showed that activation of ER via its agonists (diarylpropionitrile (DPN), Biochanin A and Genistein) was associated with increased relaxation of the vessels (thoracic aorta, inferior vena cava, descending coronary artery, aorta, mesenteric artery; and chorionic and myometrial arteries) [12–19], whereas two studies showed no effect of ER on vascular reactivity (thoracic aorta and mesenteric artery) [20,21].",
      "startOffset" : 464,
      "endOffset" : 471
    }, {
      "referenceID" : 21,
      "context" : "Furthermore, two studies showed that the effects of ER in vasodilatation are tissue-dependent: one study showed that DPN did not have any effect on relaxation of cephalic and thoracic arteries but provided a significant relaxation in abdominal arteries [22] while the second study showed that the effect of DPN was more potent in the aorta than in the mesenteric artery [14].",
      "startOffset" : 253,
      "endOffset" : 257
    }, {
      "referenceID" : 13,
      "context" : "Furthermore, two studies showed that the effects of ER in vasodilatation are tissue-dependent: one study showed that DPN did not have any effect on relaxation of cephalic and thoracic arteries but provided a significant relaxation in abdominal arteries [22] while the second study showed that the effect of DPN was more potent in the aorta than in the mesenteric artery [14].",
      "startOffset" : 370,
      "endOffset" : 374
    }, {
      "referenceID" : 15,
      "context" : "Three studies showed an endothelium-dependent effect of ER on vessel relaxation [16,17,19] while just one study reported that the relaxation caused by ER actions was largely endothelium independent [14].",
      "startOffset" : 80,
      "endOffset" : 90
    }, {
      "referenceID" : 16,
      "context" : "Three studies showed an endothelium-dependent effect of ER on vessel relaxation [16,17,19] while just one study reported that the relaxation caused by ER actions was largely endothelium independent [14].",
      "startOffset" : 80,
      "endOffset" : 90
    }, {
      "referenceID" : 18,
      "context" : "Three studies showed an endothelium-dependent effect of ER on vessel relaxation [16,17,19] while just one study reported that the relaxation caused by ER actions was largely endothelium independent [14].",
      "startOffset" : 80,
      "endOffset" : 90
    }, {
      "referenceID" : 13,
      "context" : "Three studies showed an endothelium-dependent effect of ER on vessel relaxation [16,17,19] while just one study reported that the relaxation caused by ER actions was largely endothelium independent [14].",
      "startOffset" : 198,
      "endOffset" : 202
    }, {
      "referenceID" : 11,
      "context" : "Three studies showed that relaxation of the vessel due to ER activation was NO-dependent [12,18,19] whereas three other studies showed that vasodilatation due to ER activation was not dependent on NO [13,14,16].",
      "startOffset" : 89,
      "endOffset" : 99
    }, {
      "referenceID" : 17,
      "context" : "Three studies showed that relaxation of the vessel due to ER activation was NO-dependent [12,18,19] whereas three other studies showed that vasodilatation due to ER activation was not dependent on NO [13,14,16].",
      "startOffset" : 89,
      "endOffset" : 99
    }, {
      "referenceID" : 18,
      "context" : "Three studies showed that relaxation of the vessel due to ER activation was NO-dependent [12,18,19] whereas three other studies showed that vasodilatation due to ER activation was not dependent on NO [13,14,16].",
      "startOffset" : 89,
      "endOffset" : 99
    }, {
      "referenceID" : 12,
      "context" : "Three studies showed that relaxation of the vessel due to ER activation was NO-dependent [12,18,19] whereas three other studies showed that vasodilatation due to ER activation was not dependent on NO [13,14,16].",
      "startOffset" : 200,
      "endOffset" : 210
    }, {
      "referenceID" : 13,
      "context" : "Three studies showed that relaxation of the vessel due to ER activation was NO-dependent [12,18,19] whereas three other studies showed that vasodilatation due to ER activation was not dependent on NO [13,14,16].",
      "startOffset" : 200,
      "endOffset" : 210
    }, {
      "referenceID" : 15,
      "context" : "Three studies showed that relaxation of the vessel due to ER activation was NO-dependent [12,18,19] whereas three other studies showed that vasodilatation due to ER activation was not dependent on NO [13,14,16].",
      "startOffset" : 200,
      "endOffset" : 210
    }, {
      "referenceID" : 15,
      "context" : "A single study reported that the vessel relaxation induced by DPN was not mediated via the thromboxane receptor pathway [16].",
      "startOffset" : 120,
      "endOffset" : 124
    }, {
      "referenceID" : 25,
      "context" : "One study reported a role of ER on vessel relaxation via extracellular signal-regulated kinase/mitogen activated protein kinase (ERK/MAPK) and phosphatidylinositol3 kinase (PI3K) activation [26].",
      "startOffset" : 190,
      "endOffset" : 194
    }, {
      "referenceID" : 24,
      "context" : "Two studies reported a direct involvement of ER in mediating vasodilatation exerted by estrogen [25,27]; one study reported that ER may exert a hitherto unrecognised inhibitory influence on the acute dilatory response to estrogen achieved through down regulation of ER -mediated NO release [27].",
      "startOffset" : 96,
      "endOffset" : 103
    }, {
      "referenceID" : 26,
      "context" : "Two studies reported a direct involvement of ER in mediating vasodilatation exerted by estrogen [25,27]; one study reported that ER may exert a hitherto unrecognised inhibitory influence on the acute dilatory response to estrogen achieved through down regulation of ER -mediated NO release [27].",
      "startOffset" : 96,
      "endOffset" : 103
    }, {
      "referenceID" : 26,
      "context" : "Two studies reported a direct involvement of ER in mediating vasodilatation exerted by estrogen [25,27]; one study reported that ER may exert a hitherto unrecognised inhibitory influence on the acute dilatory response to estrogen achieved through down regulation of ER -mediated NO release [27].",
      "startOffset" : 290,
      "endOffset" : 294
    }, {
      "referenceID" : 30,
      "context" : "Two studies using ER agonists [31,34] reported an increase in eNOS expression due to the activation of ER whereas",
      "startOffset" : 30,
      "endOffset" : 37
    }, {
      "referenceID" : 33,
      "context" : "Two studies using ER agonists [31,34] reported an increase in eNOS expression due to the activation of ER whereas",
      "startOffset" : 30,
      "endOffset" : 37
    }, {
      "referenceID" : 13,
      "context" : "[14] Wistar rat and mouse 29 ND Intact Thoracic aorta and mesenteric artery Vascular reactivity: vasodilatation",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 72,
      "context" : "[74] Mouse 34 10 weeks Ovariectomized Heart (transverse aortic constriction) Protein/gene expression in cardiovascular system 5 Bansal et al.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 19,
      "context" : "[20] Sprague Dawley rat 54–72 ND Ovariectomized Thoracic aorta • Vascular reactivity: vasodilatation • Inflammation/oxidative stress",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 90,
      "context" : "[92] Mouse ND 10 weeks and 52 weeks NA Vascular smooth muscle cell (aorta) • Inflammation • Role of age",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 47,
      "context" : "[49] Mouse 63 ND Intact Heart • Endothelial function and healing: angiogenesis • Inflammation",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 50,
      "context" : "[52] Mouse 16 4–6 weeks Ovariectomized Common carotid artery Endothelial function and healing: angiogenesis",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 53,
      "context" : "[55] Mouse 30 12 Ovariectomized Cerebral, cerebellar and microvascular",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 54,
      "context" : "[56] Mouse 12 12 Ovariectomized Cerebral endothelium cells Endothelial function and healing: protein/gene expression",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 58,
      "context" : "[60] Sprague Dawley Rat 11 ND Intact Vascular smooth muscle cell from aorta Endothelial function and healing: • Smooth muscle cell proliferation/apoptosis • Protein/gene expression",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 26,
      "context" : "[27] Mouse 25 14–22 week Intact Femoral artery Vascular reactivity: vasodilatation",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 22,
      "context" : "[23] Mouse 15 4 weeks Ovariectomized Thoracic aorta • Vascular reactivity: Vasodilatation • Endothelial-derived relaxing factor",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 8,
      "context" : "[9] Mouse 45 12 weeks Intact Heart and human cardiomyocyte Protein/gene expression in cardiovascular system",
      "startOffset" : 0,
      "endOffset" : 3
    }, {
      "referenceID" : 9,
      "context" : "[10] Mouse 60 9 weeks Intact Heat/cardiomyocyte Protein/Gene expression in cardiovascular system",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 29,
      "context" : "[30] Mouse 4 Adult Ovariectomized Heart Protein/Gene expression in cardiovascular system",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 70,
      "context" : "[72] Sprague Dawley rat 6 Adult Intact Ventricular myocytes from heart Protein/Gene expression in cardiovascular system",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 10,
      "context" : "[11] Mouse 5 10 week Intact Aorta/Heart Vascular reactivity: blood pressure",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 49,
      "context" : "[51] Mouse 17 Ovariectomized Coronary artery ligation and bone",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 61,
      "context" : "[63] Sprague Dawley rat ND 8 week Intact Smooth muscle cells from aorta • Endothelial function and healing: angiogenesis • Endothelial-derived relaxing factor",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 87,
      "context" : "[89] Sprague Dawley rat 34 9–11 weeks Intact &",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 89,
      "context" : "[91] Mouse 20 23–24 months (old) Intact Plasma from retro-orbita sinus plexus Inflammation/oxidative stress",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 38,
      "context" : "[40] Mouse 71 18 weeks Ovariectomized Descending aorta/Heart • Vascular reactivity: blood pressure • Protein/gene expression in cardiovascular system",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 28,
      "context" : "[29] Mouse 36 16 weeks Intact Heart Endothelial function and healing: • Proliferation/apoptosis • Protein/gene expression",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 14,
      "context" : "[15] Mouse 36 15 weeks Intact Cerebral artery Endothelial function and healing: • Proliferation/apoptosis • Protein/gene expression",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 67,
      "context" : "[69] Ovine 8 120–147 days Intact Uterine artery endothelial cells Inflammation",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 73,
      "context" : "[75] Mouse 8 2 months Intact Heart (transverse aortic constriction) • Protein/gene expression in cardiovascular system",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 74,
      "context" : "[76] Mouse 16 9 week Intact Heart (transverse aortic constriction) Protein/gene expression in cardiovascular system",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 68,
      "context" : "[70] Wistar rat 27 8 weeks ovariactomized Left anterior descending artery Inflammation 36 Li et al.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 42,
      "context" : "[44] Sprague Dawley Rat ND 3 months Intact Smooth muscle cells from aorta Endothelial function and healing: smooth muscle cell",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 48,
      "context" : "[50] Mouse ND 3 months ovariactomized Thoracic aorta Endothelial function and healing: protein/gene expression",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 55,
      "context" : "38 Lin, [57] Mouse 15 8 weeks Ovariectomized Heart Protein/gene expression in cardiovascular system",
      "startOffset" : 8,
      "endOffset" : 12
    }, {
      "referenceID" : 75,
      "context" : "[77] Mouse 12 11–12 weeks Ovariectomized Heart Protein/gene expression in cardiovascular system",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 37,
      "context" : "[39] Mouse 47 14–22 weeks Intact Femoral arteries Vascular reactivity: adrenergic control",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 23,
      "context" : "[24] Mouse 47 14–22 weeks Intact Femoral arteries Vascular reactivity: vasodilatation 42 Ma et al.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 59,
      "context" : "[61] Wistar Rat ND 7 day Ovariectomized Smooth muscle cells of carotid artery Endothelial function and healing: smooth muscle cell",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 76,
      "context" : "[78] Mouse 44 3 months Ovariectomized Heart (with ischemia reperfusion",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 24,
      "context" : "[25] Mouse 6 6–7 months Intact Abdominal aorta Vascular reactivity: vasodilatation 47 Nudelling et al.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 27,
      "context" : "[28] Rat ND 1–2 day Intact Cardiomyocite Protein/gene expression in cardiovascular system",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 86,
      "context" : "[88] Mouse ND 2,5–11,5 months Ovariectomized Total aortic RNA Protein/gene expression in cardiovascular system",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 78,
      "context" : "[80] Mouse ND ND Ovariectomized Cardiac fibroblasts Protein/gene expression in cardiovascular system 51 Pedram et al.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 60,
      "context" : "[62] Sprague Dawley Rat Intact Vascular smooth muscle cells of",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 41,
      "context" : "[43] Mouse 89 ND Ovariectomized Left coronary artery/heart • Vascular reactivity: blood pressure • Protein/gene expression in cardiovascular system",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 80,
      "context" : "[82] Mouse ND 9–10 weeks Intact Murine cardiomyocite cell line HL-1",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 12,
      "context" : "[13] Sprague Dawley Rat 6 12 week Intact Inferior vena cava Vascular reactivity: vasodilatation",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 83,
      "context" : "[85] Mouse 42–54 6 weeks Ovariectomized Aorta/THP-1 human macrophages",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 21,
      "context" : "[22] Sprague Dawley Rat ND 12 weeks Intact Cephalic, thoracic and abdominal",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 16,
      "context" : "[17] Fisher Rat ND ND Ovariectomized Abdominal aorta • Vascular reactivity: vasodilatation • Endothelial function and healing: proliferation/apoptosis protein/gene expression",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 51,
      "context" : "[53] Mouse 6 10–11 weeks Ovariectomized Transient middle cerebral artery • Protein/gene expression in cardiovascular system • Endothelial function and healing: protein/gene",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 81,
      "context" : "[83] Mouse (transverse aortic constriction) 49 7 weeks Intact Heart (transverse aortic constriction) • Protein/gene expression in cardiovascular system",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 84,
      "context" : "[86] Sprague Dawley Rat 32 8 weeks Ovariectomized Blood from vena cava • Protein/gene expression in cardiovascular system",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 15,
      "context" : "[16] Swine 8–20 ND Intact Left anterior descending coronary",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 82,
      "context" : "[84] Mouse 20 12–20 weeks Intact Heart • Protein/gene expression in cardiovascular system • Inflammation",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 85,
      "context" : "[87] Mouse 60 3 weeks Ovariectomized Heart (transverse aortic constriction) Protein/gene expression in cardiovascular system",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 17,
      "context" : "[18] Sprague Dawley Rat 8 ND Intact Aorta (collected from a region 1.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 65,
      "context" : "[67] Sprague Dawley Rat ND 10 weeks Intact Aortic smooth muscle cell Inflammation",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 66,
      "context" : "[68] Sprague Dawley Rat ND 10 weeks Intact Aortic smooth muscle cell Inflammation",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 52,
      "context" : "[54] Ewe ND 145 days Intact Uterine artery endothelial cells Endothelial function and healing: protein/gene expression",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 43,
      "context" : "[45] ND ND ND Endothelial progenitor cells Endothelial function and healing: • Angiogenesis • Protein/gene expression",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 30,
      "context" : "[31] ND ND Pre-menopausal Umbilical vein endothelial cells • Endothelial function and healing: protein/gene",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 92,
      "context" : "[94] 55 >18 years old Pre and post-menopausal Coronary artery • Atherosclerosis",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 18,
      "context" : "[19] NA ND Premenopausal Chorionic plate arteries and myometrial arteries Vascular reactivity: Vasodilatation",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 34,
      "context" : "[35] 2 23 and 44 years old Pre-menopausal Cutaneous vascular smooth muscle cell Vascular Reactivity: adrenergic control",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 44,
      "context" : "[46] ND ND ND Human retinal microvascular endothelial cell and a mouse model of oxygen induced retinopathy (n = 18–30, intact) Endothelial function and healing: angiogenesis",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 45,
      "context" : "[47] NA ND ND Endometrium endothelial cells, uterine myometrial microvascular endothelial cells, umbilical vein endothelial",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 46,
      "context" : "[48] ND ND Pre-menopausal Umbilical vein endothelial cell Endothelial function and healing: • Angiogenesis • Protein/gene expression",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 64,
      "context" : "[66] 22 ND Postmenopausal Smooth muscles cells of abdominal aorta Endothelial function and healing: smooth muscle cell",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 91,
      "context" : "[93] 68 58 ± 13 Postmenopausal Uterine arteries Inflammation",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 32,
      "context" : "[33] N ND Pre-menopausal Umbilical vein endothelial cell Endothelial-derived relaxing factor 13 Ortmann et al.",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 62,
      "context" : "[64] ND ND Pre-menopausal Smooth muscle cells from Aorta Endothelial function and healing: • Smooth muscle cell proliferation/apoptosis • Protein/gene expression",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 33,
      "context" : "[34] ND ND Pre-menopausal Umbilical vein endothelial cells Endothelial-derived relaxing factor",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 55,
      "context" : "[57] ND ND ND Villous endothelial cells Endothelial function and healing: • Protein/gene expression",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 63,
      "context" : "[65] ND ND Pre-menopausal Umbilical vein endothelial cells Endothelial function and healing: smooth muscle cell",
      "startOffset" : 0,
      "endOffset" : 4
    }, {
      "referenceID" : 27,
      "context" : "nother study [28] using ER antagonist showed a decrease in NOS expression.",
      "startOffset" : 13,
      "endOffset" : 17
    }, {
      "referenceID" : 14,
      "context" : "Three knockout mouse model studies reported decrease in eNOS expression [15,30] and phosphorylation [29] ue to the deletion of the ER gene.",
      "startOffset" : 72,
      "endOffset" : 79
    }, {
      "referenceID" : 29,
      "context" : "Three knockout mouse model studies reported decrease in eNOS expression [15,30] and phosphorylation [29] ue to the deletion of the ER gene.",
      "startOffset" : 72,
      "endOffset" : 79
    }, {
      "referenceID" : 28,
      "context" : "Three knockout mouse model studies reported decrease in eNOS expression [15,30] and phosphorylation [29] ue to the deletion of the ER gene.",
      "startOffset" : 100,
      "endOffset" : 104
    }, {
      "referenceID" : 30,
      "context" : "Activation of ER via an ER agonist id not have any effect on iNOS or nNOS expression [31] but the use f an ER antagonist was associated with lower iNOS expression 28].",
      "startOffset" : 85,
      "endOffset" : 89
    }, {
      "referenceID" : 31,
      "context" : "One study examined the correlation between ER expression n the internal mammary artery and NOS but found none [32].",
      "startOffset" : 110,
      "endOffset" : 114
    }, {
      "referenceID" : 15,
      "context" : "Increase in NO expression with activation of ER via R agonist was reported in two studies [16,34] whereas two other tudies showed no change in NO expression [31,33].",
      "startOffset" : 90,
      "endOffset" : 97
    }, {
      "referenceID" : 33,
      "context" : "Increase in NO expression with activation of ER via R agonist was reported in two studies [16,34] whereas two other tudies showed no change in NO expression [31,33].",
      "startOffset" : 90,
      "endOffset" : 97
    }, {
      "referenceID" : 30,
      "context" : "Increase in NO expression with activation of ER via R agonist was reported in two studies [16,34] whereas two other tudies showed no change in NO expression [31,33].",
      "startOffset" : 157,
      "endOffset" : 164
    }, {
      "referenceID" : 32,
      "context" : "Increase in NO expression with activation of ER via R agonist was reported in two studies [16,34] whereas two other tudies showed no change in NO expression [31,33].",
      "startOffset" : 157,
      "endOffset" : 164
    }, {
      "referenceID" : 14,
      "context" : "One study [15] eported a decrease in NO production due to the deletion of ER ene whereas another study reported no effect [23].",
      "startOffset" : 10,
      "endOffset" : 14
    }, {
      "referenceID" : 22,
      "context" : "One study [15] eported a decrease in NO production due to the deletion of ER ene whereas another study reported no effect [23].",
      "startOffset" : 122,
      "endOffset" : 126
    }, {
      "referenceID" : 34,
      "context" : "One study (using human tissue) (Suppleental Table 1B) investigated the role of ER agonist in -2C drenoreceptors expression and reported an increased expression f these receptors [35] ( -2C adrenoreceptors are located on the ascular smooth muscle cells of certain blood vessels and binds oth norepinephrine and epinephrine [36].",
      "startOffset" : 178,
      "endOffset" : 182
    }, {
      "referenceID" : 35,
      "context" : "One study (using human tissue) (Suppleental Table 1B) investigated the role of ER agonist in -2C drenoreceptors expression and reported an increased expression f these receptors [35] ( -2C adrenoreceptors are located on the ascular smooth muscle cells of certain blood vessels and binds oth norepinephrine and epinephrine [36].",
      "startOffset" : 322,
      "endOffset" : 326
    }, {
      "referenceID" : 37,
      "context" : "One study examined the effect of R gene deletion on adrenergic control of arteries (mice femoral issue) and showed no effect [39] (Supplemental Table 1B).",
      "startOffset" : 125,
      "endOffset" : 129
    }, {
      "referenceID" : 10,
      "context" : "There were two studies that examned the role of ER gene deletion on blood pressure regulation r hypertension (Table 2 and Supplemental Table 1B); one study eported that deletion of the ER gene was associated with hyperension (aorta tissue) [11] whereas the other did not report any ffect on systolic blood pressure (coronary artery tissue) [43].",
      "startOffset" : 240,
      "endOffset" : 244
    }, {
      "referenceID" : 41,
      "context" : "There were two studies that examned the role of ER gene deletion on blood pressure regulation r hypertension (Table 2 and Supplemental Table 1B); one study eported that deletion of the ER gene was associated with hyperension (aorta tissue) [11] whereas the other did not report any ffect on systolic blood pressure (coronary artery tissue) [43].",
      "startOffset" : 340,
      "endOffset" : 344
    }, {
      "referenceID" : 42,
      "context" : "Five studies (1 animal model study [44] and 4 human model studies [45–48]) focused on the role of ER agonists (DPN, Ginsenoside Rb1) in angiogenesis.",
      "startOffset" : 35,
      "endOffset" : 39
    }, {
      "referenceID" : 43,
      "context" : "Four studies [44,46–48] showed anti-angiogenic effects of the ER agonist whereas one study [45] reported no effect on capillary formation (Supplemental Table 2A).",
      "startOffset" : 91,
      "endOffset" : 95
    }, {
      "referenceID" : 47,
      "context" : "Two of these studies [49,50] reported no effect and one study [51] reported a reduction in capillary density after the deletion of the ER gene (Supplemental Table 2A).",
      "startOffset" : 21,
      "endOffset" : 28
    }, {
      "referenceID" : 48,
      "context" : "Two of these studies [49,50] reported no effect and one study [51] reported a reduction in capillary density after the deletion of the ER gene (Supplemental Table 2A).",
      "startOffset" : 21,
      "endOffset" : 28
    }, {
      "referenceID" : 49,
      "context" : "Two of these studies [49,50] reported no effect and one study [51] reported a reduction in capillary density after the deletion of the ER gene (Supplemental Table 2A).",
      "startOffset" : 62,
      "endOffset" : 66
    }, {
      "referenceID" : 50,
      "context" : "Also, one study[52] showed that ER did not mediate the effect of estrogen in angiogenesis (Supplemental Table 2A).",
      "startOffset" : 15,
      "endOffset" : 19
    }, {
      "referenceID" : 43,
      "context" : "Seven studies (4 animal model studies [17,53–55] and 3 human model studies [45,47,48]) focused on the role of ER agonists on the expression of proteins or genes associated with angiogenesis (Table 2 and Supplemental Table 2B).",
      "startOffset" : 75,
      "endOffset" : 85
    }, {
      "referenceID" : 45,
      "context" : "Seven studies (4 animal model studies [17,53–55] and 3 human model studies [45,47,48]) focused on the role of ER agonists on the expression of proteins or genes associated with angiogenesis (Table 2 and Supplemental Table 2B).",
      "startOffset" : 75,
      "endOffset" : 85
    }, {
      "referenceID" : 46,
      "context" : "Seven studies (4 animal model studies [17,53–55] and 3 human model studies [45,47,48]) focused on the role of ER agonists on the expression of proteins or genes associated with angiogenesis (Table 2 and Supplemental Table 2B).",
      "startOffset" : 75,
      "endOffset" : 85
    }, {
      "referenceID" : 16,
      "context" : "One study [17] reported that activation of ER was associated with attenuation of vascular cell adhesion protein-1 (VCAM-1) and tumor necrosis alpha (TNF- ) on the rat abdominal aorta whereas no effect was shown on intracellular adhesion molecule (ICAM).",
      "startOffset" : 10,
      "endOffset" : 14
    }, {
      "referenceID" : 45,
      "context" : "In contrast, activation of ER affected the expression of ICAM in human tissue [47].",
      "startOffset" : 78,
      "endOffset" : 82
    }, {
      "referenceID" : 51,
      "context" : "One study demonstrated that ER activation was associated with decrease of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (which has been shown to increase VEGF expression) in the murine middle cerebral artery [53].",
      "startOffset" : 235,
      "endOffset" : 239
    }, {
      "referenceID" : 53,
      "context" : "Furthermore, one study reported that ER activation was associated with increased claudin-5 protein and mRNA content [55].",
      "startOffset" : 116,
      "endOffset" : 120
    }, {
      "referenceID" : 52,
      "context" : "Two studies examining the role of ER activation on s-nitrosylation (SNO) showed contradictory results: one study [54] in animal tissue reported increase in SNO protein expression whereas the other study [45] using human tissue reported no effect.",
      "startOffset" : 113,
      "endOffset" : 117
    }, {
      "referenceID" : 43,
      "context" : "Two studies examining the role of ER activation on s-nitrosylation (SNO) showed contradictory results: one study [54] in animal tissue reported increase in SNO protein expression whereas the other study [45] using human tissue reported no effect.",
      "startOffset" : 203,
      "endOffset" : 207
    }, {
      "referenceID" : 46,
      "context" : "In tissue of premenopausal women, activation of ER was associated with activation of pigment epithelium-derived factor (PEDF) [48].",
      "startOffset" : 126,
      "endOffset" : 130
    }, {
      "referenceID" : 45,
      "context" : "It reported that ER activation affected gene expression for 22 out of 99 genes associated with angiogenesis (Growth factors: GRWANG, CXL12, ECGF1, EDIL3, FGF2, GRN, MDK, PDGFB, TGFA, VEGF; Inhibitors: CXCL10, FLT1, IFNB1, SEMA3F, SERPINF1; Markers: CEACAM1, HEY1, Target: ENPP2, NRP2, TIE1, Lymph-angiogenesis: FIGF, FOXC2) [47].",
      "startOffset" : 324,
      "endOffset" : 328
    }, {
      "referenceID" : 45,
      "context" : "However, this study also showed that there were very few ER dependent genes common to more than one of the three cell lines used and that several of the shared ER -dependent genes identified were regulated in opposite directions in endometrium and myometrium cell lines [47].",
      "startOffset" : 270,
      "endOffset" : 274
    }, {
      "referenceID" : 14,
      "context" : "Four studies (3 animal model studies [15,56] and 1 human model [57]) looked at the effect of ER gene deletion on protein or gene expression associated with angiogenesis (Supplemental Table 2B).",
      "startOffset" : 37,
      "endOffset" : 44
    }, {
      "referenceID" : 54,
      "context" : "Four studies (3 animal model studies [15,56] and 1 human model [57]) looked at the effect of ER gene deletion on protein or gene expression associated with angiogenesis (Supplemental Table 2B).",
      "startOffset" : 37,
      "endOffset" : 44
    }, {
      "referenceID" : 55,
      "context" : "Four studies (3 animal model studies [15,56] and 1 human model [57]) looked at the effect of ER gene deletion on protein or gene expression associated with angiogenesis (Supplemental Table 2B).",
      "startOffset" : 63,
      "endOffset" : 67
    }, {
      "referenceID" : 14,
      "context" : "Two animal studies showed that deletion of the ER gene was associated with a decrease in both VEGF and its kinase insert domain receptors (KDR); and with a reduction in fibroblast growth factor-2 (FGF-2) [15].",
      "startOffset" : 204,
      "endOffset" : 208
    }, {
      "referenceID" : 54,
      "context" : "One animal study showed an interaction between ER and specificity factor-1 (Sp1) site of the claudin-5 receptor, which consequently induced an increase in claudin-5 expression [56].",
      "startOffset" : 176,
      "endOffset" : 180
    }, {
      "referenceID" : 55,
      "context" : "One human study showed an inverse association between ER gene deletion in cyclo-oxygenase2 (COX-2) RNA and its protein expression [57].",
      "startOffset" : 130,
      "endOffset" : 134
    }, {
      "referenceID" : 56,
      "context" : "Since eovascularization is a key factor in the development of advanced laques and is considered a risk factor for plaque rupture [58], ER gonists may be used to improve plaque stability and reduce plaque rogression by inhibiting angiogenesis.",
      "startOffset" : 129,
      "endOffset" : 133
    }, {
      "referenceID" : 57,
      "context" : "In fact, targeting ER with gonists has been reported to be valuable in the treatment of cancer y supressing vascularization [59].",
      "startOffset" : 124,
      "endOffset" : 128
    }, {
      "referenceID" : 62,
      "context" : "igration Eight studies overall (6 animal model [15,17,29,44,60–63] and 2 uman model studies [64,65]) examined the role of ER on smooth uscle cell (SMC) proliferation (6 studies), apoptosis (2 studies) nd migration (3 studies) (Supplemental Table 2C).",
      "startOffset" : 92,
      "endOffset" : 99
    }, {
      "referenceID" : 63,
      "context" : "igration Eight studies overall (6 animal model [15,17,29,44,60–63] and 2 uman model studies [64,65]) examined the role of ER on smooth uscle cell (SMC) proliferation (6 studies), apoptosis (2 studies) nd migration (3 studies) (Supplemental Table 2C).",
      "startOffset" : 92,
      "endOffset" : 99
    }, {
      "referenceID" : 16,
      "context" : "An inhibitory effect of ER agonists on SMC roliferation were reported in 3 studies [17,44,61] whereas two tudies reported no effect [60,64].",
      "startOffset" : 83,
      "endOffset" : 93
    }, {
      "referenceID" : 42,
      "context" : "An inhibitory effect of ER agonists on SMC roliferation were reported in 3 studies [17,44,61] whereas two tudies reported no effect [60,64].",
      "startOffset" : 83,
      "endOffset" : 93
    }, {
      "referenceID" : 59,
      "context" : "An inhibitory effect of ER agonists on SMC roliferation were reported in 3 studies [17,44,61] whereas two tudies reported no effect [60,64].",
      "startOffset" : 83,
      "endOffset" : 93
    }, {
      "referenceID" : 58,
      "context" : "An inhibitory effect of ER agonists on SMC roliferation were reported in 3 studies [17,44,61] whereas two tudies reported no effect [60,64].",
      "startOffset" : 132,
      "endOffset" : 139
    }, {
      "referenceID" : 62,
      "context" : "An inhibitory effect of ER agonists on SMC roliferation were reported in 3 studies [17,44,61] whereas two tudies reported no effect [60,64].",
      "startOffset" : 132,
      "endOffset" : 139
    }, {
      "referenceID" : 58,
      "context" : "Two studies focused on the role f ER agonists on cell apoptosis and showed enhancement of this rocess with activation of ER [60,65].",
      "startOffset" : 124,
      "endOffset" : 131
    }, {
      "referenceID" : 63,
      "context" : "Two studies focused on the role f ER agonists on cell apoptosis and showed enhancement of this rocess with activation of ER [60,65].",
      "startOffset" : 124,
      "endOffset" : 131
    }, {
      "referenceID" : 16,
      "context" : "Three studies reported an nti-migratory effect by ER [17,61,62].",
      "startOffset" : 53,
      "endOffset" : 63
    }, {
      "referenceID" : 59,
      "context" : "Three studies reported an nti-migratory effect by ER [17,61,62].",
      "startOffset" : 53,
      "endOffset" : 63
    }, {
      "referenceID" : 60,
      "context" : "Three studies reported an nti-migratory effect by ER [17,61,62].",
      "startOffset" : 53,
      "endOffset" : 63
    }, {
      "referenceID" : 58,
      "context" : "Two studies showed this ffect was mediated via ER playing a role on the phosphorylation f p38 [60,65] whereas two other studies reported no effect of ER n ERK phosphorylation in the mediation of anti-migration [60,64].",
      "startOffset" : 94,
      "endOffset" : 101
    }, {
      "referenceID" : 63,
      "context" : "Two studies showed this ffect was mediated via ER playing a role on the phosphorylation f p38 [60,65] whereas two other studies reported no effect of ER n ERK phosphorylation in the mediation of anti-migration [60,64].",
      "startOffset" : 94,
      "endOffset" : 101
    }, {
      "referenceID" : 58,
      "context" : "Two studies showed this ffect was mediated via ER playing a role on the phosphorylation f p38 [60,65] whereas two other studies reported no effect of ER n ERK phosphorylation in the mediation of anti-migration [60,64].",
      "startOffset" : 210,
      "endOffset" : 217
    }, {
      "referenceID" : 62,
      "context" : "Two studies showed this ffect was mediated via ER playing a role on the phosphorylation f p38 [60,65] whereas two other studies reported no effect of ER n ERK phosphorylation in the mediation of anti-migration [60,64].",
      "startOffset" : 210,
      "endOffset" : 217
    }, {
      "referenceID" : 61,
      "context" : "One study showed that ER may epress proliferation of SMC by means other than NO signaling [63] hile another study reported ER promoting the activation of propoptotic molecules [15].",
      "startOffset" : 90,
      "endOffset" : 94
    }, {
      "referenceID" : 14,
      "context" : "One study showed that ER may epress proliferation of SMC by means other than NO signaling [63] hile another study reported ER promoting the activation of propoptotic molecules [15].",
      "startOffset" : 176,
      "endOffset" : 180
    }, {
      "referenceID" : 64,
      "context" : "One study in humans focused on the role of ER on estradiol ignaling in SMC proliferation and found no effect [66].",
      "startOffset" : 109,
      "endOffset" : 113
    }, {
      "referenceID" : 65,
      "context" : "Two animal studies [67,68] focused on the role f ER agonist DPN on inflammation in vascular endothelium and MC and reported an inhibitory effect of ER on TNF- induced nflammation (Supplemental Table 3).",
      "startOffset" : 19,
      "endOffset" : 26
    }, {
      "referenceID" : 66,
      "context" : "Two animal studies [67,68] focused on the role f ER agonist DPN on inflammation in vascular endothelium and MC and reported an inhibitory effect of ER on TNF- induced nflammation (Supplemental Table 3).",
      "startOffset" : 19,
      "endOffset" : 26
    }, {
      "referenceID" : 45,
      "context" : "Another study using human ndothelial cells from the endometrium, myometrium and plaenta found that ER activation affected gene expression in 14 of he 92 genes associated with inflammation (Lipase: PCLB2; Kinase: APK3; Prostaglandin metabolism: PTGS1, PTGS2, TBXAS1; Facor: NFKB1; GPCR Receptor: LTB4R, PTAFR, PTGIR, TBXA2R: nterleukin receptor: IL1RL1; Adhesion Molecule: ICAM and TGB2) [47].",
      "startOffset" : 387,
      "endOffset" : 391
    }, {
      "referenceID" : 0,
      "context" : "One study reported no effect of ER antagonist -phenyl-5,7-bis(trifluoromethyl) pyrazolo [1] [1,5-a]pyrimidin-3l]phenol (PHTPP) on prostacyclin [69] (Supplemental Table 3).",
      "startOffset" : 88,
      "endOffset" : 91
    }, {
      "referenceID" : 67,
      "context" : "One study reported no effect of ER antagonist -phenyl-5,7-bis(trifluoromethyl) pyrazolo [1] [1,5-a]pyrimidin-3l]phenol (PHTPP) on prostacyclin [69] (Supplemental Table 3).",
      "startOffset" : 143,
      "endOffset" : 147
    }, {
      "referenceID" : 19,
      "context" : "examining the role of DPN in the thoracic aorta and left anterior descending artery reported no effect of this agonist on TNF- , interleukin-1 beta, C-reactive protein and p-cofilin levels [20,70] (Supplemental Table 3).",
      "startOffset" : 189,
      "endOffset" : 196
    }, {
      "referenceID" : 68,
      "context" : "examining the role of DPN in the thoracic aorta and left anterior descending artery reported no effect of this agonist on TNF- , interleukin-1 beta, C-reactive protein and p-cofilin levels [20,70] (Supplemental Table 3).",
      "startOffset" : 189,
      "endOffset" : 196
    }, {
      "referenceID" : 56,
      "context" : "Restenosis, a common adverse event of endovascular procedures to treat the vascular damage from atherosclerosis, is characterized by the sequence of inflammation and SMC proliferation and migration; whereas the role of SMC apoptosis in restenosis remains unclear [58,71].",
      "startOffset" : 263,
      "endOffset" : 270
    }, {
      "referenceID" : 69,
      "context" : "Restenosis, a common adverse event of endovascular procedures to treat the vascular damage from atherosclerosis, is characterized by the sequence of inflammation and SMC proliferation and migration; whereas the role of SMC apoptosis in restenosis remains unclear [58,71].",
      "startOffset" : 263,
      "endOffset" : 270
    }, {
      "referenceID" : 69,
      "context" : "Also, intimal SMC apoptosis in advanced atherosclerotic plaques may promote plaque rupture while medial apoptosis may promote aneurism formation [71].",
      "startOffset" : 145,
      "endOffset" : 149
    }, {
      "referenceID" : 69,
      "context" : "Furthermore, SMC apoptosis may be directly pro-inflammatory by triggering the release of chemoattractant and cytokines from inflammatory cells [71].",
      "startOffset" : 143,
      "endOffset" : 147
    }, {
      "referenceID" : 41,
      "context" : "ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85].",
      "startOffset" : 85,
      "endOffset" : 98
    }, {
      "referenceID" : 70,
      "context" : "ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85].",
      "startOffset" : 85,
      "endOffset" : 98
    }, {
      "referenceID" : 71,
      "context" : "ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85].",
      "startOffset" : 85,
      "endOffset" : 98
    }, {
      "referenceID" : 79,
      "context" : "ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85].",
      "startOffset" : 85,
      "endOffset" : 98
    }, {
      "referenceID" : 75,
      "context" : "ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85].",
      "startOffset" : 142,
      "endOffset" : 149
    }, {
      "referenceID" : 81,
      "context" : "ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85].",
      "startOffset" : 142,
      "endOffset" : 149
    }, {
      "referenceID" : 29,
      "context" : "ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85].",
      "startOffset" : 206,
      "endOffset" : 210
    }, {
      "referenceID" : 55,
      "context" : "ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85].",
      "startOffset" : 247,
      "endOffset" : 251
    }, {
      "referenceID" : 77,
      "context" : "ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85].",
      "startOffset" : 352,
      "endOffset" : 356
    }, {
      "referenceID" : 85,
      "context" : "ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85].",
      "startOffset" : 398,
      "endOffset" : 402
    }, {
      "referenceID" : 41,
      "context" : "ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85].",
      "startOffset" : 453,
      "endOffset" : 460
    }, {
      "referenceID" : 72,
      "context" : "ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85].",
      "startOffset" : 453,
      "endOffset" : 460
    }, {
      "referenceID" : 76,
      "context" : "ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85].",
      "startOffset" : 524,
      "endOffset" : 534
    }, {
      "referenceID" : 80,
      "context" : "ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85].",
      "startOffset" : 524,
      "endOffset" : 534
    }, {
      "referenceID" : 83,
      "context" : "ER in the heart tissue was shown to play multiple roles such as: calcium homeostasis [43,72,73,81], regulation of lipoprotein lipase activity [77,83] and regulation of fatty acid metabolism gene expression [30], S-nitrosylation protein expression [57], activation of the functional estrogen response element of lipocalin-type prostanglandin D synthase [79], bone morphogenetic protein-4 expression [87], levels of ventricular atrial natriuretic peptide [43,74] and heat shock protein 27 as well as expression of 70 proteins [78,82,85].",
      "startOffset" : 524,
      "endOffset" : 534
    }, {
      "referenceID" : 9,
      "context" : "Also, ER was reported to play a role in cardiac fibrosis and inflammation via genomic and non-genomic actions [10,49,76,78,80,82,84,86].",
      "startOffset" : 110,
      "endOffset" : 135
    }, {
      "referenceID" : 47,
      "context" : "Also, ER was reported to play a role in cardiac fibrosis and inflammation via genomic and non-genomic actions [10,49,76,78,80,82,84,86].",
      "startOffset" : 110,
      "endOffset" : 135
    }, {
      "referenceID" : 74,
      "context" : "Also, ER was reported to play a role in cardiac fibrosis and inflammation via genomic and non-genomic actions [10,49,76,78,80,82,84,86].",
      "startOffset" : 110,
      "endOffset" : 135
    }, {
      "referenceID" : 76,
      "context" : "Also, ER was reported to play a role in cardiac fibrosis and inflammation via genomic and non-genomic actions [10,49,76,78,80,82,84,86].",
      "startOffset" : 110,
      "endOffset" : 135
    }, {
      "referenceID" : 78,
      "context" : "Also, ER was reported to play a role in cardiac fibrosis and inflammation via genomic and non-genomic actions [10,49,76,78,80,82,84,86].",
      "startOffset" : 110,
      "endOffset" : 135
    }, {
      "referenceID" : 80,
      "context" : "Also, ER was reported to play a role in cardiac fibrosis and inflammation via genomic and non-genomic actions [10,49,76,78,80,82,84,86].",
      "startOffset" : 110,
      "endOffset" : 135
    }, {
      "referenceID" : 82,
      "context" : "Also, ER was reported to play a role in cardiac fibrosis and inflammation via genomic and non-genomic actions [10,49,76,78,80,82,84,86].",
      "startOffset" : 110,
      "endOffset" : 135
    }, {
      "referenceID" : 84,
      "context" : "Also, ER was reported to play a role in cardiac fibrosis and inflammation via genomic and non-genomic actions [10,49,76,78,80,82,84,86].",
      "startOffset" : 110,
      "endOffset" : 135
    }, {
      "referenceID" : 8,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 121,
      "endOffset" : 139
    }, {
      "referenceID" : 9,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 121,
      "endOffset" : 139
    }, {
      "referenceID" : 58,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 121,
      "endOffset" : 139
    }, {
      "referenceID" : 72,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 121,
      "endOffset" : 139
    }, {
      "referenceID" : 73,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 121,
      "endOffset" : 139
    }, {
      "referenceID" : 76,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 121,
      "endOffset" : 139
    }, {
      "referenceID" : 8,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 196,
      "endOffset" : 205
    }, {
      "referenceID" : 74,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 196,
      "endOffset" : 205
    }, {
      "referenceID" : 86,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 196,
      "endOffset" : 205
    }, {
      "referenceID" : 73,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 231,
      "endOffset" : 244
    }, {
      "referenceID" : 76,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 231,
      "endOffset" : 244
    }, {
      "referenceID" : 84,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 231,
      "endOffset" : 244
    }, {
      "referenceID" : 86,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 231,
      "endOffset" : 244
    }, {
      "referenceID" : 74,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 263,
      "endOffset" : 270
    }, {
      "referenceID" : 86,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 263,
      "endOffset" : 270
    }, {
      "referenceID" : 73,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 301,
      "endOffset" : 308
    }, {
      "referenceID" : 76,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 301,
      "endOffset" : 308
    }, {
      "referenceID" : 76,
      "context" : "Furthermore, ER was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene expression [9,10,60,74,75,78], modulation of genes involved in mitochondrial modeling [9,76,88], cytoskeletal regulation [75,78,86,88], oxidative stress [76,88], glucose and insulin pathways [75,78] and NO synthesis [78].",
      "startOffset" : 326,
      "endOffset" : 330
    }, {
      "referenceID" : 87,
      "context" : "Two studies reported no role of ER on stromal cell-derived factor-1 production [89] or on corticotrophin-releasing hormone receptor 2 [90] whereas one study, by using plasma from retro-orbital sinus plexus, showed that deficiency of ER may affect the energy metabolism of platelets resulting in greater production of thrombogenic microvesicles in the circulation [91].",
      "startOffset" : 79,
      "endOffset" : 83
    }, {
      "referenceID" : 88,
      "context" : "Two studies reported no role of ER on stromal cell-derived factor-1 production [89] or on corticotrophin-releasing hormone receptor 2 [90] whereas one study, by using plasma from retro-orbital sinus plexus, showed that deficiency of ER may affect the energy metabolism of platelets resulting in greater production of thrombogenic microvesicles in the circulation [91].",
      "startOffset" : 134,
      "endOffset" : 138
    }, {
      "referenceID" : 89,
      "context" : "Two studies reported no role of ER on stromal cell-derived factor-1 production [89] or on corticotrophin-releasing hormone receptor 2 [90] whereas one study, by using plasma from retro-orbital sinus plexus, showed that deficiency of ER may affect the energy metabolism of platelets resulting in greater production of thrombogenic microvesicles in the circulation [91].",
      "startOffset" : 363,
      "endOffset" : 367
    }, {
      "referenceID" : 76,
      "context" : "In contrast to the study performed in hearts [78], in which ER selective agonist upregulated 122 genes and down-regulated 23 genes, a gene array study comparing gene expression in ovariectomized mice aorta treated with estrogen showed that 90% of the genes showing an estrogen-mediated decrease, were ER dependent [88].",
      "startOffset" : 45,
      "endOffset" : 49
    }, {
      "referenceID" : 86,
      "context" : "In contrast to the study performed in hearts [78], in which ER selective agonist upregulated 122 genes and down-regulated 23 genes, a gene array study comparing gene expression in ovariectomized mice aorta treated with estrogen showed that 90% of the genes showing an estrogen-mediated decrease, were ER dependent [88].",
      "startOffset" : 314,
      "endOffset" : 318
    }, {
      "referenceID" : 90,
      "context" : "Also, two studies (one animal [92] nd one human study [93]) focused on the role of ER in inflamation as a function of age and menopausal status.",
      "startOffset" : 30,
      "endOffset" : 34
    }, {
      "referenceID" : 91,
      "context" : "Also, two studies (one animal [92] nd one human study [93]) focused on the role of ER in inflamation as a function of age and menopausal status.",
      "startOffset" : 54,
      "endOffset" : 58
    }, {
      "referenceID" : 90,
      "context" : "One study howed that estrogen through ER may inhibit inflammation in oung but not in old mice [92], whereas another human study howed an increased linear trend in ER expression with aging and ears since menopause, as well as a positive correlation between xpression of ER and inflammatory markers such as interleukin-8 nd TNF- [93].",
      "startOffset" : 94,
      "endOffset" : 98
    }, {
      "referenceID" : 91,
      "context" : "One study howed that estrogen through ER may inhibit inflammation in oung but not in old mice [92], whereas another human study howed an increased linear trend in ER expression with aging and ears since menopause, as well as a positive correlation between xpression of ER and inflammatory markers such as interleukin-8 nd TNF- [93].",
      "startOffset" : 327,
      "endOffset" : 331
    }, {
      "referenceID" : 92,
      "context" : "However, this orrelation did not differ by menopausal status [94].",
      "startOffset" : 61,
      "endOffset" : 65
    }, {
      "referenceID" : 100,
      "context" : "ies have shown that activation of ER has resulted in suppression of IL-6 promoter activity in human endothelial cancer cells in vitro and to play a role in regulation of neutrophil infiltration following acute injury [102,103].",
      "startOffset" : 217,
      "endOffset" : 226
    }, {
      "referenceID" : 101,
      "context" : "ies have shown that activation of ER has resulted in suppression of IL-6 promoter activity in human endothelial cancer cells in vitro and to play a role in regulation of neutrophil infiltration following acute injury [102,103].",
      "startOffset" : 217,
      "endOffset" : 226
    }, {
      "referenceID" : 74,
      "context" : "Additionally, ER was shown to exert the role of gatekeeper in the genomic response of the heart to pressure overload, and may thus play a protective role against cardiac hypertrophy [76].",
      "startOffset" : 182,
      "endOffset" : 186
    }, {
      "referenceID" : 110,
      "context" : "The expresion of ER nay be vulnerable to the effects of age not only in he cardiovascular system but also in other systems such as the ervous system [112].",
      "startOffset" : 149,
      "endOffset" : 154
    }, {
      "referenceID" : 110,
      "context" : "Similarly, loss of locally synthesized estrogen mainly fter menopause can affect the expression of ER [112].",
      "startOffset" : 102,
      "endOffset" : 107
    } ],
    "year" : 2016,
    "abstractText" : "Five medical databases were searched for studies that assessed the role of ER in the female cardiovascular system and the influence of age and menopause on ER functioning. Of 9472 references, 88 studies met our inclusion criteria (71 animal model experimental studies, 15 human model experimental studies and 2 population based studies). ER signaling was shown to possess vasodilator and antiangiogenic properties by regulating the activity of nitric oxide, altering membrane ionic permeability in vascular smooth muscle cells, inhibiting vascular smooth muscle cell migration and proliferation and by regulating adrenergic control of the arteries. Also, a possible protective effect of ER signaling against left",
    "creator" : "Elsevier"
  }
}